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Chapter 1
1.1 General
C hronic obstructive pulm onary disease (C O P D ) represents the diseases chronic 
bronchitis, pulm onary emphysema and peripheral airway obstruction. I t is 
characterised by abnormal tests of expiratory flow, which do no t markedly change 
over periods of several months of observation (1). C O P D  is a com m on disease; the 
estimated prevelance in Europe is 2 - 7 %  of the population. The general im pact is 
significant, as it is one of the 5 most frequent causes of death in industrialised 
countries.
C O PD  is usually a progressive disease, sometimes resulting in  a ventilatory failure 
w ith hypoxia. This is caused by 1) a mismatch between ventilation and perfusion 
(V /Q  m ism atch), 2) shunting and/or 3) a reduced diffusion capacity for oxygen can 
cause a low arterial oxygen tension (hypoxemia). Patients can develop an additional 
retention of carbon dioxide (hypercapnia), in general in a later stage, when alveolar 
hypoventilation is involved. Patients w ith severe C O PD  (FEV 1 < 50 %  predicted) can 
experience episodes of (peripheral) oedema. As soon as it occurs, the prognosis is 
getting worse; w ithout treatm ent, 2 ou t of 3 patients dies w ithin 5 years (2-5).
In the following paragraphs 1) the consequences of hypercapnia, 2) the development 
of oedema, 3) the action and the acid/base effects of loop diuretics, 4) the im pact of 
acid/base shifts on the ventilation, 5) the im pact of acid/base shifts on muscle 
function and 6) breathing during sleep in  C O PD  will be discussed. This will be 
followed by a hypothetical model dealing w ith interactions between hypercapnia, 
oedema, diuretics and acid-base shifts in C O PD  patients. In the last paragraph the 
studies, performed in this thesis to test the hypothesised interactions, will be 
outlined.
1.2 Hypercapnia in COPD
Hypercapnia generally becomes more frequent as the airflow obstruction worsens. 
However, there is a wide variety in arterial C O 2  in  patients w ith severe airflow 
obstruction (6). Several factors may explain why some patients develop hypercapnia 
and others do no t (7).
1. Increased airway resistance increases the ventilatory drive, bu t decreases the 
expired m inute ventilation at any particular level of ventilatory drive. The 
ventilatory response to changes in C O 2 may therefore be lower as the airway 
resistance increases. This implies that the final alteration in the ventilation in 
response to a certain change in C O 2 is variable, depending on the ventilatory drive
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and the airflow limitation (8,9).
2. An impaired inspiratory muscle strength has often been reported in C O PD  
(10-12). This can be ascribed to a flattening of the diaphragm due to 
hyperinflation, which causes an unfavourable position of the diaphragm on the 
length-tension diagram (10). A reduced maximal inspiratory muscle strength 
increases the risk of hypercapnia considerably. Hypercapnia, however, may further 
affect the diaphragm function (13). The net C O 2 level depends on the interaction 
between the pre-existing diaphragm function and the adverse effect of C O 2  on the 
diaphragm function.
3. Earlier studies of hypercapnic C O PD  patients have demonstrated breathing 
patterns w ith low tidal volumes and either unchanged or increased respiratory 
rates (14-16). The consequent m inute ventilation is decreased or unchanged, the 
ratio of dead space ventilation is increased and alveolar ventilation is decreased. 
The pattern of breathing in an individual patients, in response to the severity of 
the airflow limitation, determines the retention of carbon dioxide (16).
4. Inadequate chemoresponsiveness may also contribute to  the low ventilatory 
response to C O 2 in chronic hypercapnic patients (17). However, this topic is 
somewhat controversial, as others found that the resting arterial C O 2 was not 
predicted by the respiratory drive (18).
Chronic hypercapnia can become so called 'permissive’, when a controlled 
mechanical hypoventilation occurs. Priority is then given to  the prevention or 
lim itation of severe pulm onary hyperinflation over the maintenance of a normal 
alveolar ventilation (19).
Several studies show a clear association between hypercapnia and long term mortality 
(2-5). For example, Costello et al. found that the 5-yrs survival was significantly 
lower in C O PD  patients w ith chronic hypercapnia, as compared to patients with 
norm ocapnia and reversible hypercapnia (11% versus 33% and 28%  respectively) 
(4). Moreover, when data are corrected for the natural risk of death, 5-years survival 
fell from 56% in normocapnic patients to  33% in chronic hypercapnic patients (5). 
Chronic respiratory insufficiency also seems to predict hospitalization for acute 
exacerbation in C O PD  patients (20).
Hypercapnia has considerable consequences in  patients w ith C O PD  (table 1). The 
contribution to the development of oedema is of clinical relevance, as several studies 
have demonstrated an association between the presence of oedema and poor survival 
(21-25). It is unclear whether this is a reflection of the severity of disease or if oedema 
directly affects prognosis. Either way, accurate m onitoring of hypercapnic C O PD  
patients w ith signs of oedema is justified, in order to establish the optimal treatment.
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C hapter  1
System Effect Reference
Respiratory gas  exchange W orsening of hypoxem ia (7)
Cardiovascular D ecreased  system ic resistance 
D ecreased  ventricular function  
Increase in coronary  flow
(26-29)
Renal and  body fluid hom eostasis* Reduction of renal blood flow 
O edem a
(30-32)
Central nervous system Cerebral vasodilatation 
D epressed  consciousness
(7,19)
S tria ted  m uscles D ecreased  contractility 
R educed endu rance
(13,33)
Bronchial sm o o th  m uscles D ecrease of airway resistance (34)
Table 1. Consequences of hypercapnia. *: see also paragraph 1.3 for the effects of hypercapnia on the renal and body fluid 
homeostasis.
1.3 Oedema in COPD
Peripheral oedema occurs in a substantial num ber of C O PD  patients (30-32,35,36). 
Oedematous state in patients w ith C O PD  was earlier referred to as cor pulmonale. 
This was originally viewed as a right ventricular failure caused by an progressive 
pulm onary hypertension, induced by hypoxemia.
T he right and left ventricular function may also directly be affected by factors such 
as hypoxemia, hypercapnia or acidosis (28,31,37-39). However, right and left 
ventricular performances and cardiac ou tpu t are often norm al in C O PD  patients 
w ith clinical evidence of oedema (30,35,38,40,41). It is therefore likely that other 
factors are also responsible.
Hypercapnia is believed to  play a major role in the development of oedema (30­
32,42). The im pact of hypoxemia is less clear (31,32,42,43), although some studies 
suggest a direct fluid retaining effect of hypoxemia (35,44-46).
H igh levels of catecholamines and renin are com m on in oedematous C O PD  
patients. (35,42,48), which may be explained as follows. Carbon dioxide has a 
powerful vasodilatating capacity (7). A decreased systemic vascular resistance may 
inactivate baroreceptor activity and lead to a reflex increase in catecholamines 
(7,49,50). The increased sympatic activation can cause a reduction renal blood flow 
and can contribute to the release of vasopressin (51). A reduction in renal blood flow 
as m uch as 63%  has been reported in C O PD  patients (30,36,43,47). A low effective 
renal blood flow (ERBF) is accompanied by an increased filtration fraction to remain
O
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adequate clearance. Consequently the peritubular colloid oncotic pressure increases, 
which may lead to  an increased reabsorption of sodium and water causing oedema 
(43). Moreover, high levels of catecholamines and the reduced renal blood flow can 
also activate the renin-angiotensine-aldosteron-system (RAAS) (49,50). The net 
result of the high levels of catecholamines, vasopressin and activation of RAAS, with 
secondary hyperaldosteronism, is a sodium and water retention in the renal tubules. 
Respiratory acidosis due to hypercapnia is counter regulated by renal excretion of 
hydrogen (H+) and reabsorption of bicarbonate (H C O 3-). Approximately 90%  of 
the filtered bicarbonate is reabsorbed in  the proximal tubule. Sodium and water 
transport is coupled to the reabsorption of H C O 3- and follow passively (31,52,53). 
T he retention of water can contribute to the formation of oedema.
1.4 Loop diuretics
Loop diuretics, such as furosemide and bumetanide and ethacrynic acid, act by 
preventing the reabsorption of sodium in the thick ascending loop of Henle, which 
can lead to  excretion of up to 25 % of the filtered sodium (54). Because of the potent 
diuretic capacity, loop diuretics are frequently prescribed for the treatm ent of 
oedema. Loop diuretics can cause complications, such as azotemia (a rise in  urea and 
creatinine), hypokalemia and metabolic alkalosis (54,55). The development of a loop 
diuretic induced metabolic alkalosis can be explained as followed.
1. Bicarbonate is increasingly reabsorbed in the proximal tubules in relation to  the 
reabsorption of water. The contraction of the extra cellular volume around the 
same am ount of extra cellular bicarbonate is called contraction alkalosis (56).
2. Volume depletion stim ulates the activity of RAAS w ith  secondary 
hyperaldosteronism. Aldosteron contributes to  H + loss both  by stimulating the 
distal H +-ATPase pum p and by prom oting the reabsorption of sodium (57,58). 
T he latter causes an lumen-negative electrical potential which leads to an 
accumulation of H + and potassium in the tubular lumen.
Because C O PD  patients may decrease their ventilation to compensate the metabolic 
alkalosis, a higher PaC O 2 may occur (see acid-base and ventilatory control).
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Chapter 1
1.5 Acid-base and ventilatory control
The respiratory system and metabolic system are in constant interplay to stabilise the 
acid-base equilibrium. The relationship between pH , C O 2 and H C O 3- is described 
by the Henderson-Hasselbalch equation: pH  = 6.1 + log [HCO3-]/(0.03 P C O 2) (59). 
Alterations in systemic pH  may either be the cause or the consequence of alterations 
in  ventilation or renal H C O 3- changes. The relationship between C O 2 and H C O 3- 
in  a variety of clinical conditions are shown in figure 1 (60-63).
Figure 1. Relationships between HCO 3- and PaCÜ2 in a variety of clinical conditions. The bars represent the 95% 
confidence intervals of acute and chronic metabolic abnormalities. As depicted in: Effros RM, Widell JL. Acid-base 
balance. In: Murray JF, Nadel JA. (eds.): Textbook of Respiratory Medicine, Vol 1. Part 1. Philadelphia, 
W.B. Saunders Company, 175-198.
Figure 2. Block diagram of the ventilatory control system. CSF: cerebro spinal fluid; centr chemo: central 
chemoreceptors; perif chemo: peripheral chemoreceptors; centres: “respiratory centres” in pons and brainstem; RM 
motoneur: spinal motoneurones of the inspiratory muscles; IC: intercostal inspiratory muscles; Dia: diaphragm; 
Ppleura: pleural pressures; Elast: elastic properties of the lung parenchyma; Palv: alveolar pressure; Raw: airway resistance; 
VDan: anatomical deadspace; VDphys: physiological deadspace; hypothal: hypothalamus; som+visc aff: somatic and 
visceral afferents; cortex: forebrain cortex; VE: total ventilation; VA: alveolar ventilation; PaO2: arterial oxygen 
tension; PaCÜ2: arterial carbon dioxide tension; pHa: arterial pH. Source: Folgering HThM. Studying the control 
of breathing in man. Eur.Respir.J. 1988;1:651-660.
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In  case of a metabolic alkalosis, an increased level of H C O 3- requires an increase in 
C O 2 in  order to m aintain pH  within the physiological range. An adequate response 
in ventilation to changes in blood gases will be accomplished by means of ventilatory 
control (64) (figure 2). Metabolic alkalosis will result in a diminished chemoreceptor 
stim ulation (65,66), reduced m otor drive of the respiratory muscles, a decrease in 
ventilation (67), a rise in C O 2 , and finally a correction of the alkalosis. O n  the 
contrary, metabolic acidosis causes an increased chemoreceptor stimulation, an 
increased m otor drive of respiratory muscles and a decrease in PaC O 2 .
1.6 Acid-base and muscle function
Acidosis causes a decreased contractility of several types of striated muscles. (13,68­
70). The effect have been described for metabolic (68,71,72) as well as for respiratory 
acid-base changes (13,69,73). It can probably be explained as follows. Low pH  
decreases cellular influx of calcium, reduces the affinity of troponin for calcium, 
increases the calcium binding to the sarcoplasmatic reticulum and may reduce the 
rate of glycolysis and thus the ATP resynthesis (13,74). The effect of alkalosis on 
striated muscle function appears to be less obvious. Metabolic alkalosis was found to 
increase tetanic tension of skeletal muscles in some studies (75,76), bu t no t in 
another study (77). Moreover, the performance of hum an skeletal muscles seems not 
to improve after induction of metabolic alkalosis (78).
The effect of C O 2 changes on the contractility of bronchial smooth muscles are well 
documented. Hypercapnic acidosis, by hypoventilation, causes bronchodilatation 
(34). H ypocapnic alkalosis, by hyperventilation, was found to  cause 
bronchoconstriction (34,79,80), due to contraction of bronchial sm ooth muscles 
(81). Therefore, it seems that acidosis and alkalosis have opposite effects on bronchial 
sm ooth muscles. It was suggested, from an in vitro study in  isolated feline bronchial 
rings, that C O 2 effects can be ascribed to  pH  related effects (81). Primary C O 2 
changes altered the contractility of bronchial sm ooth muscles, bu t changing pH , with 
constant C O 2 , mimicked these effects. In  an other study in  anaesthetised dogs, 
isocapnic acidosis (by infusion of HCl) was equal to hypercapnic acidosis (by 
inhalation of C O 2) in its ability to inhibit bronchoconstriction (82). To date there 
have been no clinical evaluations in hum an subjects, bu t it is possible that metabolic 
acid-base shifts influence the hum an airway sm ooth muscles.
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Chapter 1
1.7 Breathing during sleep in COPD
The alveolar gas exchange can increasingly be endangered during sleep. Therefore, 
w hen evaluating the risk factors for the development of complications in C O PD , it 
is im portant to take notion of the nocturnal ventilation. The contributing of sleep 
related mechanisms in C O PD  are outlined in this paragraph.
D uring rapid eye movement (REM) sleep, there is a considerable loss in skeletal 
postural muscle tone and a decreased activity of intercostal and accessory muscles 
(81,83-86). The diaphragm escapes from this inhibition and is, in healthy subjects, 
able to compensate for the diminished activity of the other respiratory muscles 
during REM sleep (87). In patients w ith C O PD , the diaphragm is flattened because 
of hyperinflation and therefore its function is affected by the unfavourable position 
on the length-tension curve (10). The diaphragm is no t able to  compensate 
ventilation during REM  sleep in C O PD , which can result in oxygen desaturation 
(88-92). The relationship between respiratory muscle function and nocturnal 
hypoventilation was clearly demonstrated in a study, showing the benefit of target- 
flow inspiratory muscle training on nocturnal oxygen saturation in C O PD  patients 
w ith nocturnal hypoventilation (93). V /Q  mismatch may also be present during 
sleep, due to a reduced airway clearance and/or a lower functional residual capacity 
w ith airway compression (94). This may explain why slight oxygen desaturations also 
occur during non-REM  episodes.
1.8 Hypothetical model
The potential interactions between fluid retention, acid-base regulation and 
ventilatory control in  C O PD  are illustrated in figure 3. A substantial num ber of 
hypoxemic and hypercapnic C O PD  patients develop peripheral oedema (30­
32,35,36). In general practice, loop diuretics are frequently prescribed to reduce the 
oedema. The metabolic alkalosis, induced by loop diuretics, may have serious 
implications in  C O P D  patients.
A. A metabolic alkalosis causes a diminished chemoreceptor stim ulation (65,66) 
and, as a result, a reduced alveolar ventilation (67). In spite of a physiological 
mechanism for restoring the acid-base equilibrium, this may worsen the pre­
existing hypercapnia and hypoxemia in C O PD  patients. The effect of decreasing 
ventilation  on blood gases may be m ore pronounced at night, since 
hypoventilation is often seen during sleep in C O PD  (88-92). This may be more 
severe in case of a metabolic alkalosis.
O
Introdution
B. Metabolic alkalosis may increase contractility of bronchial sm ooth muscle cells 
(81). A constriction of bronchial sm ooth muscles may cause a reduction of the 
airway calibre. The constrictive effect of metabolic alkalosis on airways may cause 
a worsening of the pre-existing V /Q  mismatch. The alveolar gas exchange may be 
further endangered.
Since hypoxemia and hypercapnia are associated w ith the development of oedema, 
patients may develop an increased tendency towards fluid retention. This may 
counteract the diuretic effects of furosemide. The hypothesised phenom ena may 
m aintain or become more serious. This may also have long term implication, as 
hypercapnia is clearly associated w ith long term m orbidity and mortality (2-5). 
Patients may experience a further deterioration of an already poor clinical condition.
Figure 3. Hypothetised interactions between ventilation, acid-base and body water.
1.9 Aims of the thesis
The general aim of the thesis was to clarify the presence of the hypothesised 
interactions, as described above and presented in figure 3.
W hen using nocturnal oxygen saturation as an outcom e variable, one needs to 
consider the im pact of disturbing measuring conditions during the m onitoring 
night. M onitoring equipm ent (application of transducers on the patient) and or an
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Chapter 1
unfamiliar hospital environment may cause disturbances in sleep w ith frequent 
arousals and wakefulness (95-98). This may prevent deep sleep and REM  sleep and 
result in fewer oxygen desaturations during the monitoring night. As a result, an 
overestimation of the mean nocturnal oxygenation may be found. The aim of chapter 
2 was to evaluate the im pact of the m onitoring equipm ent and the unfamiliar 
hospital environm ent on the assessment of nocturnal oxygen saturation. The 
conclusions of this study were applied to the study, in chapter 4, to perform the 
nocturnal measurements in the most reliable way.
It is difficult to quantify the severity of peripheral oedema in clinical patients, as no 
accurate tools are available for this purpose. It was demonstrated earlier that water- 
displacement volumetry is a cheap and accurate m ethod for quantifying the volume 
the hum an leg (99-103). However, the application of the m ethod in clinical patients 
w ith peripheral oedema has no t been described yet. The aim of chapter 3 was to 
validate the m ethod to  quantify  the severity of peripheral oedem a of 
cardiopulmonary origin in clinical conditions. This study allowed a methodological 
basis for the use of the tool in the studies, described in chapter 4 and 7.
It was hypothesized that the metabolic alkalosis due to the use of furosemide causes 
a decreased ventilation, resulting in an increased PaC O 2 and a worsening of 
oxygenation. The aim of chapter 4 was to evaluate if discontinuing loop diuretics, 
prescribed for peripheral edema in C O PD  patients w ith a mean nocturnal SaO 2 < 
92%, could result in a correction of this phenom enon. Discontinuing furosemide 
was expected to increase alveolar ventilation, and therefore to  decrease PaC O 2 and 
increase daytime and nocturnal oxygenation.
The effect of metabolic acid-base shifts on the hum an airway caliber was evaluated 
in  chapter 5. Acute metabolic acidosis and alkalosis were induced in healthy hum an 
subjects by am m onium  chloride and bicarbonate respectively. The effects of the 
interventions on the airway resistance and conductance were measured as primary 
variables. Secondary, the bronchoconstrictive response to histamine and respiratory 
and peripheral muscle strength were also evaluated.
Chapter 6 is directly related to  chapter 5, by evaluation of the effects in patients with 
asthma or C O PD . The same interventions were used as in chapter 5 and, in addition, 
an acute metabolic alkalosis was induced by furosemide to assess the clinical relevance 
of a furosemide induced alkalosis on airway calibre.
Since hypercapnia plays a major role in the development of peripheral oedema in 
patients w ith C O PD , it is likely that decreasing PaC O 2 leads to resolution of oedema. 
A recent study by Thorens et al. showed that ventilatory support, by non-invasive 
ventilation, could resolve oedema in patients w ith hypercapnia, probably by
O
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correction of blood gases. However, these patients recovered from a worsening of 
chronic hypercapnia of various origin (104). The benefit of non-invasive ventilation 
on the body water homeostasis in patients w ith chronic hypercapnic C O PD  is not 
known. C hapter 7 evaluates the effect of 24 hours non-invasive ventilation via a nasal 
mask, on the correction of hypercapnia. We aimed to  evaluate if this was adequate to 
resolve superfluous of body water in chronic hypercapnic C O PD  patients.
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2.1 Summary
C O P D  patients run  a risk of developing nocturnal oxygen desaturation. W hen 
evaluating patients w ith nocturnal hypoxemia, an unfamiliar hospital environment 
and the m onitoring equipm ent may cause sleep disturbances. It was hypothesised 
that increased sleep disruption will lead to fewer instances of desaturations during a 
night of monitoring.
The following forms of monitoring were evaluated prospectively on 3 nights for each 
patient: Oximetry at home; polysomnography (PSG) at home; and PSG in the 
hospital. Fourteen stable C O PD  patients [7 men; median age 71.5; age range 59 to
81 years; FEV 1: 32.5; FEV 1 range 19 to 70 % predicted] participated in the study. 
All subjects had significant instances of nocturnal arterial oxygen desaturation. Those 
patients w ith a sleep-related breathing disorders or cardiac failure were excluded form 
the study.
The mean nocturnal arterial oxygen saturation (SaO 2) level was higher during PSG 
m onitoring at home (89.7%; range 77 to 93%) than during oximetry monitoring 
(88.5%; range 80 to 92%) [p<0.025]. Fraction of time in  hypoxemia (ie, Sa02<90%) 
was lower during PSG m onitoring at home (40.8%; range 5 to 100%) than during 
oximetry m onitoring (59.9%; range 6 to 100%) [p<0.01]. Desaturation time (delta 
Sa02>4%) was lower during PSG m onitoring at home (22.1%; range 3 to 63%) 
during oximetry m onitoring (50.4%; range 4 to 91%) [p<0.01]. A correction for 
actual sleep during PSG m onitoring reduced the differences between PSG 
m onitoring at home and oximetry monitoring, although a difference in the 
desaturation tim e remained (PSG m onitoring at home, 31.9%  [range 2 to 75%]; 
oximetry m onitoring 50.4% [range 4 to 91%]) [p=0.041]. A comparison of sleep 
architectures for nights when PSG was being m onitored showed a higher arousal 
index in the hospital than at home (PSG m onitoring in hospital 5.6 arousals per hour 
[range 2 to 16 arousals per hour], PSG m onitoring at home 2.5 arousals per hour 
[range 1 to 6 arousals per hour]) [p<0.025], bu t no differences in Sa02 levels were 
found between PSG m onitoring at home and PSG m onitoring in the hospital.
The artifacts due to sleep m onitoring equipm ent may cause an underestim ation of 
the degree of nocturnal hypoxemia in C O PD  patients. The addition of an unfamiliar 
environm ent causes more sleep disruption, bu t this does no t affect nocturnal SaO 2 
levels further.
o
Underestim ation o f  n octurn al hypoxem ia due to m onitoring conditions in  pa tients with C O P D
2.2 Introduction
Patients w ith C O PD  run a risk of developing nocturnal hypoxemia. This can be 
explained by alveolar hypoventilation (1-3) and by ventilation/perfusion mismatch 
(4,5). Alveolar hypoventilation occurs predom inantly during rapid eye movement 
(REM) sleep. Ventilation/perfusion mismatch can occur during non-REM  sleep 
episodes as well. The relevance of evaluating nocturnal hypoxemia in C O PD  is still 
under debate, as yet, no studies have shown the benefit of correcting isolated 
hypoxemia on long term mortality rates. However, evaluation of the degree of 
nocturnal hypoxemia can be needed, as it clearly seems to be associated with 
complications, such as arrhythmia, polycythemia, pulm onary hypertension, and 
peripheral edema (6). Furthermore, the correction of nocturnal hypoxemia by 
supplemental oxygen was found to reduce pulm onary artery pressure in a study 
evaluating C O PD  patients whose daytime Pa02 was above 60 m m H g (7). It is 
im portant to assess the severity of nocturnal hypoxemia in C O PD  accurately, as a 
value of > 30% of time spent in hypoxemia is causally related to perm anent 
pulm onary hypertension (8). W hen measuring nocturnal oxygen saturation, the 
monitoring conditions may cause disturbances in sleep architecture. Studies on 
polysomnography (PSG) show a delayed sleep onset, sleep fragmentation, frequent 
arousals, and shortened periods of REM sleep as compared to a normal sleep cycle in 
a comparable age group (9-12). It is unclear to  w hat extent these sleep disturbances 
can be attribu ted  to  m onitoring  equipm ent or to an unfam iliar hospital 
environment. Because of these sleep disturbances, the first m onitoring night is often 
used for acclimatization. In  patients w ith C O PD , however, repeated measurements 
during consecutive and nonconsecutive nights in the sleep laboratory show a similar 
change in sleep architecture and nocturnal oxygen saturation (2, 13, 14). If sleep is 
disturbed, wakefulness and arousals may prevent oxygen desaturations in  patients 
w ith C O PD . As a result, an overestimation of the mean nocturnal oxygenation may 
be found. It was hypothesized that both m onitoring equipm ent and an unfamiliar 
hospital environment may have a disturbing effect on sleep, resulting in fewer 
instances of oxygen desaturation. To distinguish both  effects, three different 
conditions were evaluated: oximetry at home; PSG at home; and PSG in hospital. 
First, it was expected that the addition of polysomnographic equipm ent in  the home 
situation would result in fewer instances of desaturation, as compared to m onitoring 
w ith oximetry alone. Second, it was expected also that the unfamiliar environment 
during PSG monitoring in hospital would result in  fewer instances of desaturation 
than during PSG m onitoring at home.
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2.3 Materials and methods
2.3. Study design
The effects of sleep m onitoring conditions were evaluated in 14 patients w ith C O PD  
during 3 nights in the following order: (1) oximetry at home; (2) PSG in the hospital 
sleep laboratory; and (3) PSG at home. An interval of at least 2 days was maintained 
between the different nights, in order to rule out compensatory sleep after sleep 
deprivation. The median duration of the study 24 days (range 6 to 36 days). Alcohol 
and coffee were prohibited on the evening of the m onitoring nights. Medication 
remained unchanged during the course of the study.
Sex, males :females 7:7
Age, years 72 (59-81)
Height, cm 164(155-182)
Weight, kg 73.0(61-100)
Body Mass Index (BMI) 26.8 (20.1-41.7)
FEV1, % predicted 32.5 (19-70)
FEV1/VC, % 45.5 (23-70)
Daytime PaCO2, kPa /  mmHg 6.2 (5.0-7.7) /  46.5 (37.5-57.8)
Daytime PaO2, kPa /  mmHg 8.6 (6.0-9.4) /  64.5 (45-70.5)
Daytime SaO2, % 91.5 (78-95)
Sleep apnea/hyponea index, 1/hr 0.3 (0-3.2)
Table 1. Subject characteristics. All results represent median (range) values.
2.3 .2  Subjects
The study was performed on 14 stable C O P D  patients, who were selected 
consecutively from the outpatient department. C O PD  was defined according to the 
standards of the American Thoracic Society (15). All subjects had a smoking history 
of > 10 pack-years (smokers 3 patients; ex-smokers 11 patients). O ther characteristics 
of the study population are presented in Table 1. Stability of the disease was defined 
as a fluctuation in FEV 1 < 10% in the preceding 3 months and an absence of 
exacerbation in the preceding 8 weeks befor the study began. None of the patients 
were oxygen-dependent. Subjects w ith a history of obstructive or central apneas or 
an overlap syndrome were excluded. Those w ith a history of cardiac failure also were 
excluded, and an ultrasound of the heart was performed to rule ou t current cardiac 
failure.
Subjects were visited for oximetry at home (n=60). The hypothesized effects of the 
m onitoring conditions could only be evaluated if nocturnal oxygen desaturations 
were present, which, consequently, left room  for improvement. Therefore, subjects
Underestim ation o f  n octurn al hypoxem ia due to m onitoring conditions in  pa tients with C O P D
continued participation in the study if the mean nocturnal SaO 2 was < 92%  (n= 17). 
The other subjects were excluded. The second m onitoring night consisted of the PSG 
m onitoring performed in the hospital. Subjects were excluded if a sleep apnea /  
hypopnea syndrome, defined as an apnea /  hypopnea index > 15 /hour, was found 
(16). Although no t clinically suspect, three subjects needed to  be excluded at this 
stage of the study: one had an obstructive sleep apnea syndrome, one had an 
obstructive hypopnea syndrome and one had a central apnea syndrome. The 
remaining subjects completed the study w ith the third m onitoring night using PSG 
at home (n=14). The study protocol was approved by the hospital ethics committee. 
A w ritten informed consent was obtained from all subjects.
2.3 .3  Measurements
Oximetry was performed at night using the same portable pulse oximeter (model 
8500M , N onin Medical Inc., Plymouth, M innesota, USA). Values were measured by 
a finger probe. Subjects were instructed to switch the oximeter on and off at the same 
tim e each night to m atch the recorded tim e during the 3 nights. SaO 2 values were 
stored in memory and processed afterwards using appropriate software (N N856 
03/95, PROFO X  associates Inc., Escondido, CA, USA).
PSG in hospital (Voyageur, Nicolet Biomedical Inc., Madison, Wisconsin, USA) was 
perform ed in  the sleep laboratory. T he electroencephalogram  (EEG), the 
electrooculogram (EOG), and the mental electromyogram (EMG) were recorded to 
determine sleep states and assessed manually by the neurology laboratory technicians, 
according to  the guidelines of Rechtschaffen and Kales (17). Respiration was 
m onitored by thoraco-abdom inal movements, using inductive plethysmography 
(1482, Pro-Tech Services Inc., Woodinville Washington, USA), and by airflow 
thermistors (Infinity sensor 1450, New Life Technologies Inc., M idlothian, Virginia, 
USA). Oximetry was performed simultaneously.
PSG at home (model 9000, Oxford Instrum ents Medical Systems, Abingdon, 
O xfordshire, UK) included EEG, electrom yogram , electro-oculogram  and 
simultaneous oximetry. Thoraco-abdom inal movements and airflow were not 
measured at home.
The severity of nocturnal hypoxemia was evaluated by the following primary 
variables: the mean nocturnal SaO 2 value, the fraction of tim e spent in hypoxemia 
(ie, SaO2<90%) and the fraction of tim e spent in desaturation. A desaturation was 
defined as a decrease in SaO 2 of more than 4% from the first 5 m inutes of the 
recording (baseline awake) (14). The baseline asleep was defined as the first 5 minutes 
of continuous sleep after the first onset of sleep state II. Arousals were defined
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according to the preliminary recom mendations of the American Academy of Sleep 
Medicine (formerly known as American Sleep Disorder Association) (18).
Since no sleep states were measured during the night of oximetry, SaO 2 variables were 
only presented for the entire night. The assessment of the sleep states during the 
nights of PSG allowed a calculation of these variables during actual sleep (REM + 
non-REM ) and during REM sleep specifically as well. If the mean SaO 2 level during 
the entire night differed between oximetry and PSG values, an additional comparison 
was performed between the PSG values during actual sleep and the oximetry values 
for the entire night, to determine whether this correction of the PSG results allowed 
a more reliable assessment of nocturnal SaO 2 values.
The daytime PaO 2 , SaO 2 and the baseline awake SaO 2 were correlated to the mean 
nocturnal SaO 2 value during the different nights, in order to evaluate the predictive 
value of these variables for assessing the degree of nocturnal hypoxemia.
2.3.4 Statistics
For statistical analysis, an appropriate software package (SPSS, version 6.1 (SPSS 
Inc., Chicaco, IL, USA) was used. Since we aimed to evaluate the equipm ent effect 
(ie, oximetry versus PSG at home) and the environment effect (ie, PSG at home 
versus PSG in the hospital) differences between 2 nights were compared selectively 
by paired t tests or by Wilcoxon signed rank tests if no t normally distributed. A p- 
value < 0.025 was considered statistically significant, because 2 selective comparisons 
were performed. P values between 0.025 and 0.05 are presented as true values.
A Pearson correlation was used to perform bivariate correlation analysis or a 
Spearman correlation if values were no t normally distributed. All results are expressed 
as median (range).
2.4 Results
2.4.1 Oximetry versus PSG at home
The mean SaO 2 , the fraction of time spent in hypoxemia and the fraction of time 
spent in desaturation were statistically significantly different, showing lower SaO 2 
values during oximetry than during PSG m onitoring at home (Table 2). Thirteen 
subjects spent > 30% in hypoxemia during oximetry monitoring, as compared to 9 
during PSG m onitoring at home. The fraction of tim e spent desaturated decreased 
by more than half during PSG m onitoring (22.1%; range 3 to 63%) compared to 
oximetry m onitoring (50.4%; 4 to 91%) [p<0.01]. The individual values of the time 
in  hypoxemia and the time in desaturation are presented in Figure 1 and 2
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respectively.
The SaO 2 values were corrected for actual sleep during PSG m onitoring at home and 
compared to those for the entire night of oximetry m onitoring (Table 3). In this 
recalculation, the mean SaO 2 value showed no statistically significant difference. The 
fraction of time spent desaturated remained lower during PSG at home, bu t this did 
no t reach statistical significance [p=0.041].
2.4 .2  PSG a t home versus PSG in  hospital
The PSG recordings allowed a detailed description of the sleep architecture and 
demonstrated more arousals in hospital than at home (hospital 5.6 arousals per hour; 
range 2 to 16 arousals per hour; home 2.5 arousals per hour; range 1 to 6 arousals 
per hour) [p<0.025, Table 4]. A more disturbed sleep architecture also was suggested 
from an increased total num ber of arousals and a lower am ount of tim e spent in 
REM  sleep, bu t these did no t reach complete statistical significance [p = 0.038 and 
p = 0.041, respectively].
N o statistically significant difference in SaO 2 values were found during the entire 
night or during actual sleep (table 2). However, when evaluating REM sleep, a higher 
fraction of tim e in desaturation was found when m onitoring took place in the 
hospital (73.1%; range 37 to 100%) vs home (44.8%; range 2 to 99%) [p<0.025].
1. Oxim etry 2. PSG a t hom e 3. PSG in hospital P,1 vs 2 P, 2 vs 3
Entire night
Baseline awake SaO2, % 92.0 (88-97) 92.1 (82-94)) 93.1 (87-95) NS NS
Mean SaO2, % 88.5 (80-92) 89.7 (77-93) 89.9 (79-94) <0.025 NS
Fraction of tim e in hypoxemia, % 59.9 (6-100) 40.8 (5-100) 39.3 (0-100) <0.01 NS
Fraction of tim e in desaturation, % 50.4 (4-91) 22.1 (3-63) 16.6 (0-92) <0.01 NS
Lowest SaO2, % 73 (40-85) 74 (51-85) 78 (40-86) NS NS
Actual sleep
Baseline asleep SaO2, % 90.7 (75-93) 90.0 (79-94) NS
Mean SaO2, % 89.2 (75-92) 88.5 (78-93) NS
Fraction of tim e in hypoxemia, % 47.1 (6-100) 69.1 (5-100) NS
Fraction of tim e in desaturation, % 31.9 (2-75) 25.5 (1-94) NS
Lowest SaO2, % 76 (51-85) 78 (53-86) NS
REM sleep
Mean SaO2, % 86.9 (70-91) 86.8 (77-90) NS
Fraction of tim e in hypoxemia, % 71.4 (16-100) 82.8 (37-100) NS
Fraction of tim e in desaturation, % 44.8 (2-99) 73.1 (37-100) <0.025
Lowest SaO2, % 78 (51-86) 79 (60-86) NS
Table 2. Nocturnal SaO 2 during different nights. Results represent median (range) values. PSG: polysomnography. SaO 2 values, 
specified for actual sleep and REM sleep, were not applicable for oximetry .
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Oxim etry 
(entire night)
PSG a t hom e 
(actual sleep)
p-value
M ean SaO 2 , % 88.5 (80-92) 89.2 (75-92) NS
Fraction of tim e  in hypoxem ia, % 59.9 (6-100) 47.1 (6-100) NS
Fraction of tim e  in desa tu ra tion , % 50.4 (4-91) 31.9 (2-75) 0.041
Low est SaO 2 , % 73 (40-85) 76 (51-85) NS
Table 3. Nocturnal SaO 2 during the entire night of oximetry and during actual sleep of PSG at home. Results represent median 
(range) values. PSG: polysomnography.
PSG a t hom e PSG in hospital p-value
Sleep latency, min 23.5 (12-127) 50.0 (3-101) NS
A ctual s leep  tim e, hrs 5.5 (3-8) 6.3 (2-8) NS
Arousals, to ta l num ber 15.0 (5-28) 21.0 (6-108) 0.038
Arousal index, 1 /hour 2.5 (1-6) 5.6 (2-16) <0.025
Sleep efficiency, %
Sleep s ta te s  d u ring  sleep, %
66.0 (46-96) 72.0 (43-95) NS
Non-REM, s leep  I + II 66.8 (60-89) 64.3 (55-89) NS
Non-REM, s leep  III + IV 16.1 (3-29) 19.9 (4-30) NS
REM sleep 17.6 (5-24) 11.5 (7-27) 0.041
Table 4. Sleep architecture during polysomnography. Results represent median (range) values. PSG: polysomnography.
Oxim etry PSG a t hom e PSG in hospital
r p R P r p
D aytim e PaO 2 versus NSaO 2 0.58 0.031 0.66 <0.025 0.43 NS
D aytim e SaO 2 versus NSaO 2 0.74 <0.01 0.70 <0.01 0.63 <0.025
Baseline aw ake versus NSaO 2 0.89 <0.001 0.78 <0.01 0.85 <0.001
Table 5. Correlation between daytime and nocturnal oxygenation. PSG: polysomnography. NSaO 2 : nocturnal SaO 2 .
2.4 .3  Correlation o f daytime and nocturnal oxygenation
The correlation’s between daytime oxygenation variables and nocturnal SaO 2 are 
shown in Table 5. The strongest correlation was found between the baseline awake 
SaO 2 and the mean nocturnal SaO 2 .
2.5 Discussion
The purpose of this study was to  determine the effect of sleep monitoring conditions 
on the assessment of nocturnal SaO 2 values in patients w ith C O PD . Equipm ent had 
a significant impact, as lower SaO 2 values were found during oximetry monitoring
Underestim ation o f  n octurn al hypoxem ia due to m onitoring conditions in  pa tients with C O P D
than during PSG m onitoring at home. The addition of an unfamiliar environment 
seems to have no further impact, as no significant differences in SaO 2 values were 
found between PSG m onitoring at home and PSG m onitoring in the hospital.
It was hypothesized that m onitoring equipm ent would cause sleep disturbances and, 
consequently, prevent oxygen desaturations. Polysomnographic equipm ent was 
added to oximetry in the familiar home situation and these were compared to 
oximetry alone. A disturbed sleep was found during PSG monitoring, which is in 
agreement w ith the hypothesis. The median sleep tim e was 5.5 h. This is rather low, 
taking into account a norm al sleep tim e of 6-6.5 h at this age (19). The median 
fraction of time in REM  sleep was 17.6 %, as compared to 20-23 %, which is 
com m on at this age in normal subjects (19).
100 1 i t
• f K O .D I
odnoÈy PSG «  huma
Figures 1 an d 2. Fraction of time in hypoxemia and fraction of time in desaturation during oximetry and PSG at 
home in the individual subjects.The thin lines represents an individual subject, the thick line the median of the 
group. PSG: polysomnography
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As expected, the nocturnal SaO 2 value was lower during oximetry m onitoring than 
during PSG m onitoring. The differences in  the mean SaO 2 values were rather small, 
bu t the time spent desaturated decreased by more than half from 47.5 % (oximetry) 
to  20.9 % (PSG). The SaO 2 values during polysomnography were corrected for 
actual sleep, to determine if this resulted in a more reliable assessment of nocturnal 
SaO 2 . The modified SaO 2 values approximated the data attained for the entire night 
of oximetry m onitoring. Although no t completely statistical significant, the fraction 
of tim e spent in desaturation remained higher during oximetry monitoring, which 
may suggest the presence of longer periods of REM sleep or non-REM  sleep state III 
and IV during home oximetry monitoring.
A correlation analysis was performed between the daytime PaO 2 and SaO 2 values and 
the baseline awake SaO 2 and the mean nocturnal SaO 2 values in  order to evaluate the 
predictive value of these variables for assessing the degree of nocturnal hypoxemia. 
The predictive values of daytime PaO 2 and SaO 2 for assessing the degree of nocturnal 
hypoxemia were statistically significant bu t rather poor, which is in agreement with 
earlier studies (20,21). The correlation between the baseline awake SaO 2 and the 
mean nocturnal SaO 2 was stronger for all evaluated nights. This may suggest that a 
short recording made w ith the patient in bed in the evening provides a better 
prediction for assessing the degree of nocturnal hypoxemia.
It was also hypothesized that the addition of an unfamiliar hospital environment 
would influence the assessment of nocturnal SaO 2 levels. PSG m onitoring in the 
unfamiliar hospital environment was, therefore, compared to PSG m onitoring at 
home. Sleep was more disturbed in hospital than at home, as indicated by the PSG 
m onitoring higher arousal index. A higher total num ber of arousals and a lower 
fraction of time in REM  sleep were also found during PSG in hospital, bu t these 
differences did no t reach complete statistical significance. As oxygen desaturations 
occur mainly during REM  sleep (1-3), a lower fraction of time spent in REM sleep 
was expected to  result in fewer desaturations and higher SaO 2 values for monitoring 
performed in the hospital. However, the mean nocturnal SaO 2 values during the 
entire night or during actual sleep were no t different between monitoring performed 
in  the hospital and that performed at home. Apparently, the variation in sleep 
architecture was too small to cause significant differences in  mean SaO 2 values. This 
is obvious, when it is taken into account that PSG m onitoring in the hospital 
comprised more equipm ent than  that performed at home. M onitoring performed in 
the hospital included measurements of thoraco-abdom inal movements and airflow as 
well. It appears that the addition of an unfamiliar environment has no further 
artificial effect on the recorded SaO 2 values, even when SaO 2 is evaluated in
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com bination w ith an expanded set of equipment. A num ber of portable sleep study 
systems have been validated for use w ith patients who have obstructive sleep apneas 
or hypopneas, mainly because of benefit in time and cost (22). Although no t all 
devices record sleep quality, OSAS patients may sleep better at home than in  the sleep 
laboratory (23). In contrast to previous studies evaluating patients w ith sleep apneas 
or hypopneas, the present study describes patients w ith C O PD . The disturbed 
quality of sleep during polysomnography corresponds well w ith previous findings (9­
12,23). It is interesting to note that poor quality of sleep was reported as a com m on 
feature in C O PD  patients (24-27). The authors note that the sleep disturbances may 
be caused by other factors, such as hypoxemic stress. The present results clearly show 
lower nocturnal SaO 2 values during oximetry m onitoring than during PSG 
monitoring. This suggests a disturbing effect of m onitoring equipm ent on the quality 
of sleep, especially the am ount of REM  sleep. Hospital environmental factors were 
found to disturb sleep (28). In agreement w ith this, our results show more sleep 
disturbances during monitoring in the hospital than at home.
The study nights occurred in a fixed sequence. However, a potential order effect can 
certainly no t explain the difference shown in SaO 2 values between the study nights. 
Subjects may have experienced some general unfamiliarity w ith the study, causing 
some sleep disruption, mainly during the first night. Still m ost desaturations were 
found during oximetry monitoring, which was the first night of study in our design. 
A randomized order, w ith oximetry performed during the second or the third night, 
could possibly have resulted in an improved sleep com fort and even more 
desaturations. A first night effect however, was no t found in a study evaluating 
C O PD  patients during consecutive and nonconsecutive nights (14). It is unlikely 
that the sequence of the nights was influenced the measured findings, bu t the 
findings may w arrant a future study, that would be conducted in a randomized 
design w ith a larger group of C O PD  patients.
PSG m onitoring is no t a routine investigation in C O PD  to evaluate the degree of 
nocturnal hypoxemia, as no studies have showed the benefit of correcting isolated 
nocturnal hypoxemia on longterm outcome. Nevertheless, nocturnal hypoxemia in 
C O PD  can be associated w ith complications, such as arrhythmia, polycythemia, 
pulm onary hypertension or peripheral edema (6). Because supplemental oxygen 
therapy reduces the pulm onary artery pressure in C O PD  patients w ith isolated 
nocturnal hypoxemia, recognizing patients at risk can be im portant (7). A value of > 
than 30%  of tim e spent in  hypoxemia proved to be causally related to perm anent 
pulm onary hypertension in C O PD  (8). Thirteen of our subjects spent > 30%  of their 
tim e in hypoxemia during oximetry m onitoring, compared to 9 during PSG
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m onitoring at home, suggesting that 4 of the 13 subjects (31%) at risk would have 
been missed looking at PSG monitoring. Therefore, the performance of home 
oximetry monitoring as the m ethod of choice for evaluating the degree of nocturnal 
hypoxemia in C O PD  patients is of clinical importance. It can be performed easily, it 
is cheap and, as this study shows, it provides reliable information. A wider use of 
nocturnal home oximetry m onitoring may reveal many C O PD  patients w ith severe 
nocturnal hypoxemia who are unknow n or have no t been detected by PSG 
m onitoring. Moreover, home oximetry may serve as an appropriate tool for 
evaluating the longterm benefit of treating nocturnal hypoxemia. O ne needs to 
consider that full PSG m onitoring is still needed, as patients exeriencing an overlap 
syndrome (ie. the simultaneously presence of C O P D  and OSAS) are at high risk of 
developing respiratory insufficiency and pulm onary hypertension (6,29). Regarding 
the fact that three subjects needed to be withdrawn from our study, it appears that a 
sleep disorder is hard to rule out in the absence of clear clinical evidence. The SaO 2 
values probably will be higher during PSG monitoring. A correction for actual time 
asleep may allow a more reliable, bu t still incomplete, assessment of nocturnal SaO 2 
levels.
In conclusion, when m onitoring nocturnal SaO 2 levels in patients w ith C O PD , the 
im pact of the sleeping conditions needs to be taken into account. It seems that 
m onitoring equipm ent has a substantially more confounding effect on the assessment 
of nocturnal SaO 2 levels than does an unfamiliar environment. Sleep disturbances 
can prevent oxygen desaturation and can cause an underestim ation of the degree of 
nocturnal hypoxemia in  patients w ith C O PD .
Acknowledgement: We thank Frans L.A. Willekes, MSc. and Theo M. de Boo, MSc. 
for their advice on the statistical analysis.
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C hapter 3
Volumetric measurements of peripheral 
oedema in clinical conditions.
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3.1 Summary
Water-displacement volumetry can be used for quantifying the volume of the leg. 
N ot m uch is known about the application in patients w ith peripheral oedema of 
cardiopulmonary origin.
We measured the reproducibility of a water-displacement apparatus w ith a solid 
object and in 10 non-oedem atous clinical patients (A). The day-to-day variability of 
the leg volume was assessed in the same group. T he diurnal variability was assessed 
in  10 patients w ith persisting peripheral oedema (B). The effect of treatm ent on the 
severity of peripheral oedema was evaluated in another 9 patients w ith peripheral 
oedema, who were in need of diuretic treatm ent (C). All volumetric results were 
compared to the ankle circumference m ethod and the body weight method.
The coefficient of variation was 0.16%  in the fixed object and 0.47%  in group A. 
The day-to-day variability was 1.52% after 1 day and 1.76% after a mean interval of 
4.8 days. In group B, leg volume and circumference increased during the day (5.9%, 
p<0.001 and 2.4%, p<0.01 respectively), while body weight remained unchanged. In 
group C, leg volume, circumference and body weight decreased significantly after 
treatm ent (13.1%, p<0.01, 7.1%, p<0.05, and 5.9%, p<0.05). The correlation 
between the changes in volume and body weight was poor (r=0.37, p=0.33).
It was concluded that 1) water-displacement volumetry is highly reproducible, 2) a 
diurnal variability of peripheral oedema was found, and 3) volumetry is a suitable 
tool for m onitoring peripheral oedema, while the body weight method appears to be 
less accurate.
3.2 Introduction
A tool is needed to quantify the severity of peripheral oedema when this is the main 
parameter for m onitoring the course of the disease or the effect of treatment.
D ata of the volume of the hum an leg can be obtained by either indirect methods 
based on circumference measurements or directly by volumetry. Several indirect 
methods have been described as mathematical methods; In the frustum-sign method 
the application of the formula for a truncated cone is used (1). The disk model 
m ethod is based on a sum of disk volumes in  which the leg can be virtually divided 
(2). Volumetry can be performed by using the opto-electronic or the water- 
displacement technique. Opto-electronic volumetry is sophisticated (3) bu t rather 
complex and expensive. Water displacement volumetry is a cheap and accurate
o
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m ethod (4-9). Using this principle, the lower leg volume can be measured by 
recording water displacement after immersion of the lower leg in a water bath. The 
volume can then be quantified by collecting the water overflow (4,5,7), by 
calculating the differences of the water level on a calibrated scale (6) or by directly 
determining the increase in  hydrostatic pressure, caused by immersion of the leg on 
a scale (9).
Earlier studies describe accuracy, differences between dom inant and non-dom inant 
legs and biological variation during the day as well as between days (2,9-11). These 
results were acquired in healthy volunteers. Less is known about the clinical 
application in patients w ith peripheral oedema of cardiopulmonary origin. Firstly, it 
is unclear to what extent fluctuations in peripheral oedema can influence the results. 
Secondly, it is unclear which decrease of the lower leg volume can be ascribed to 
treatment.
T he aim of our study was threefold;
1) Validating an apparatus, based on the principle of water displacement volumetry.
2) Assessing the diurnal variability of the leg volume in  patients w ith persisting 
peripheral oedema, as compared to  the ankle circumference m ethod and the body 
weight method.
3) Assessing the effect of diuretic therapy on the severity of peripheral oedema, 
measured by volumetry, the ankle circumference m ethod and the body weight 
m ethod.
3.3 Methods
3.3.1 Apparatus
A perspex water bath (produced in the Rijnstate Hospital), measuring 42 x 42 x 42 
cm, was used in which both feet could be immersed simultaneously (figure 1). A tap 
was placed in one of the walls, 18 cm from the bottom . A block of foam was 
positioned in the bath, fixed below the water surface, for the following reasons: a) 
T he relative contribution of the volume of the lower legs in  the water increased, 
resulting in  more water displacement. This could increase the accuracy of the 
m ethod. b) The block was positioned between the legs and the tap. The waves in the 
water level, due to leg movements, could therefore be diminished before reaching the 
tap. Lukewarm water of 25-27°C was used to fill the bath because the temperature 
of the skin approximates this value. W hen the procedure was started, the bath was 
filled to a level ju s t above the tap. The tap was opened until the water stopped 
running. Then, the sitting subjects immersed their lower legs in the bath, after
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closing the tap. D uring the procedure, subjects were seated on a hospital bed with 
their knees bent at an angle of 90°, to ensure reproducible placing and pressure. The 
water overflow after opening the tap again, that resulted from the rise of the water, 
was collected and weighed on an electronic scale (M ettler Toledo PR5002DR, 
accuracy 0.1 g, long-term stability 0.0015 %).
Figure 1. Water-displacement volumetry.
The body weight was measured, after voiding, by using a Seca 761 medical scale 
(accuracy 100 g). The ankle circumference was measured, w ith a measuring tape, at
10.0 cm above the sole and calculated as the mean of both ankles. The agreement 
between the two-dimensional measurements (ankle circumference method) and the 
three-dimensional (volumetry) measurements was evaluated by using the disk model 
m ethod (2).
3.3.2 Subjects 
Validation (group A)
The reproducibility of the volumetric procedure and the day-to-day variability were 
tested in 10 clinical patients (6 males) w ith a mean (SD) age of 65 (12.1), range 42­
82 and w ithout signs of peripheral oedema. The reasons for admission were bronchial 
carcinoma (n=3), pneum onia and respiratory infection (n=3), pneum othorax (n=2) 
and carcinoma of the breast (n=2). N one of the subjects received diuretics.
9
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D iurnal variability (group B)
T he diurnal variability of peripheral oedema was measured in 10 clinical patients (4 
males) w ith a mean (SD) age of 79 (10.6), range 57-89 and w ith persisting pitting 
oedema (table 1). Subjects were only included if the dose of diuretics and the dietary 
intake of sodium had remained the same for at least a week preceding the study. 
Patients w ith signs of chronic venous insufficiency or ulcers, and those using 
orthopaedic stockings were excluded.
Effect of diuretic therapy on the severity of oedema (group C).
The effect of diuretic therapy on the severity of oedema was measured in another 9 
clinical patients (3 males) w ith a mean (SD) age of 73 (11.3), range 52-88, in whom 
diuretic therapy was started or in whom an increase in dose of diuretics was indicated 
(table 2). Patients receiving calcium channel blockers were excluded.
Patient num ber Sex Age (yrs) D iagnosis T reatm ent
1 F 87 CHD (arrhythm ia and  valvular insufficiency) 1,2
2 F 67 COPD an d  cor pu lm onale 1
3 F 85 CHD (arrhythm ia and  valvular insufficiency) 1
4 M 87 CHD (arrhythm ia and  hypertensia) 1
5 M 73 CHD (post myocardial infarction) 1,2,3
6 M 87 COPD an d  cor pu lm onale 1
7 F 83 CHD (arrhythm ia and  valvular insufficiency) 1
8 M 89 COPD an d  cor pu lm onale 1
9 F 57 COPD an d  cor pu lm onale 1
10 F 79 CHD (atrial fibrillation, no o th e r cause  found) 1,3
M ean (SD) 79 (11)
Table 1. Demographic characteristics of patients with persisting oedema (group B).Treatment: 1: furosemide 40 mg or bumetanide
1 mg, 2: spironolacton, 3: ACE inhibitor. CH D : congestive heart disease
Patient num ber Sex Age (yrs) D iagnosis T reatm ent
1 M 76 CHD (post myocardial infarction) 2,3,4
2 F 67 CHD (post myocardial infarction) 2,3,4
3 F 52 CHD (dilating card iom yopathy  of unknow n origin) 1,3,4
4 F 88 CHD (arrhythm ia and  hypertensia) 2,3,4
5 M 66 COPD an d  cor pu lm onale 1,3
6 F 71 CHD (post myocardial infarction) 2,3
7 M 72 COPD an d  cor pu lm onale 1
8 F 81 CHD (post myocardial infarction) 2,3
9 F 87 CHD (prim ary supraventricu lar arrhythm ia) 2,3
m ean  (SD) 73 (11)
Table 2. Demography and treatm ent strategy of patients in need of diuretic treatm ent (group C).Treatment: 1: furosemide 40 mg, 
bumetanide 1 mg, 2: furosemide > 40 mg or bumetanide > 1 mg, 3: spironolacton, 4: ACE inhibitor. CH D : congestive heart disease
o
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3.3.3 Procedure 
Validation
The reproducibility of refilling the bath was evaluated by measuring a solid object 10 
times, after refilling the bath each time. The coefficient of variation (CV), defined as 
[SD /  mean] x 100%, was calculated to determine the reproducibility.
The reproducibility of measuring the lower leg volume was tested by three successive 
recordings in each patient in  group A. The CV was calculated for each individual. 
The day-to-day variability was measured in group A by comparing foot volumetry on 
three different days. The results of the first day were compared to those on the second 
day and ju s t before discharge (mean (SD) 4.8 days (2.7), range 2-10). The day-to- 
day variability was defined as: [V(volume d,, x - volume d,, 0 ) 2 /  volume d,, 0] x 100%. 
The reproducibility of the scale was tested by measuring a metal block 10 times at
8.00 and at 17.00 hrs.
D iurnal variability in patients w ith peripheral oedema.
Volumetry, the body weight method as well as the ankle circumference method were 
performed in group B immediately after rising at 8.00, and then at 9.00, 10.00,
11.00 and at 17.00 hour. Body weight was measured after voiding. D uring the day 
the subjects were encouraged to keep their legs low and to lie down as little as 
possible. Subjects were no t allowed to wear shoes during the day of measurements. 
Diuretics were administered at 8.00 p.m.
The diurnal variability was defined as: [V(volume 17.00 - volume 8.00)2 /  volume 8 .00] x 
100%. T he agreem ent betw een the tw o-dim ensional m easurem ents (ankle 
circumference method) and the three-dimensional (volumetry) measurements was 
evaluated by calculating a linear regression analysis and Pearson correlation 
coefficient.
Effect of diuretic therapy on the severity of oedema
Measurements, including volumetry, ankle circumference and body weight, were 
performed in group C at the same time of the day on day 1 and day 8 of the 
admission. The physical activity preceding the test on day 8 was matched to the test 
on day 1.
3.3.4 Statistics
Differences were tested by the paired t-test. Correlation between two parameters was 
tested by the Pearson correlation. A p-value < 0.05 was considered to be significant. 
All results are expressed as mean (SD). For analysis the SAS package (SAS Institute 
Inc. Cary, N orth  Carolina, USA) was used.
o
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3.4 Results
3.4.1 Validation
T he volume of the object, measured 10 times, was 1357 (2) ml, w ith a range of 
1354-1360 ml.
The CV was 0.16 %. The volume of the lower legs was 2473 (12) ml, w ith a range 
of 1900-3090 ml. The mean CV in the 10 individuals was 0.47 %.
The variability after the short interval (day 1- day 2) was 1.52 (1.1) %, w ith a range 
of 0.26-3.78 %, and 1.76 (0.79) %, w ith a range of 0.74-3.12, after the longer 
interval (day 1 - discharge). The latter was no t significantly larger than the one-day 
variability (p=0.63).
The mean weight of the metal block was 24.0 (0.048) kg at 8.00 and 24.0 (0.063) 
kg at 17.00. The CV of the results, measured by the scale, was 0.20 % and 0.26 % 
respectively.
3.4.2 D iurnal variability
The leg volume was 2780 (300) m l at 8.00 hrs and 2943 (299) ml at 17.00 hrs 
(p<0.001). This increase during the day of 164 (88) ml, range 11-301 ml, was 5.9 % 
of the initial value.
The ankle circumference was 25.0 (1.4) cm at 8.00 hrs and 25.6 (1.3) cm and 17.00 
hrs (p<0.01). This increase of 0.6 (0.5) cm, range 0-1.7 cm, was 2.4 % of the initial 
value.
The body weight remained the same during the day. The trends during the day of the 
leg volume, the ankle circumference and the body weight are presented in figure 2. 
The calculated increase in volume, corresponding to the measured increase in ankle 
circumference was 4.9 %, as compared to the actual increase in volume of 5.9 % 
(intercept = -0.7, slope=0.84, r=0.71, p<0.05), measured by the volumetric method.
3.4.3 Effect o f diuretic therapy
Significant decreases were found in all three parameters when the values after 
treatm ent were compared to those before treatm ent (figure 3);
- Lower leg volume: 2715 (570) ml, and 3125 (594) ml, difference 13.1 % (p<0.01).
- Ankle circumference: 24.8 (3.4) cm, and 26.7 (3.5) cm, difference 7.1 % (p<0.05).
- Body weight: 66.8 (15.8) kg, and 71.0 (16.2) kg, difference 5.9 % (p<0.05).
The mean change in the lower leg volume was 2.2 times greater than the diurnal 
variability and 7.4 times greater than the day-to-day variability in patients with 
persisting oedema. A poor correlation was found between the changes in volume and
Ch
ap
ter
 
3
Lo
op
 
di
ur
eti
cs
 a
nd 
hy
pe
rc
ap
ni
a 
in 
ch
ro
ni
c 
ob
str
uc
tiv
e 
pu
lm
on
ar
y 
di
se
as
e.
Chapter 3
changes in body weight (intercept=2.5, slope=0.39, r=0.37, p=0 .33). The correlation 
between the changes in volume and the changes in ankle circumference was 
significant (intercept=2.5, slope=1.41, r=0.68, p<0.05).
volunwby
tm  1--------------------------------
m  ------— -------
ankb eteumlM iiict
body vnight
Figure 2: Diurnal variability in leg volume, ankle circumference and body weight. Upper lines: trends of leg 
volume. M iddle lines: trends of ankle circumference. Lower lines: trends of body weight. Each continuous line 
represents 1 patient (group B), each dotted line represents mean values.
O
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Discussion
W ater-displacement volumetry is a cheap and accurate method, which is relatively 
easy to perform.
This study demonstrates the clinical application of the method in patients with 
peripheral oedema of cardiopulmonary origin. The volumetric apparatus was found 
to be highly reproducible. A significant increase during the day was found in the leg 
volume and the ankle circumference. An evaluation of the response to treatm ent 
demonstrated a significant decrease in  leg volume, ankle circumference and in body 
weight. The greatest decrease was found in the data of the water-displacement 
volumetry.
1D5
100 
95
□-
»
85 
SC
Je£ volume uncumifei'ence f?íHÍy vuei^ iL
Figure 3. Response to  treatm ent.The results represent mean values before (white bars) and after (black lines) 
treatment, as fractions of the initial values (group C). * p  < 0.05 **p < 0.01.
The accuracy of refilling our apparatus proved to be in the same range as the results 
of others; we found a coefficient of variation of 0.16 % as compared to earlier reports 
(9,2,11) who found 0.09 %, 0.38 % and 0.44 % respectively. The present results of 
the reproducibility in  healthy subjects are similar to those of others, although a wide 
range can be found in the literature. We found a coefficient of variation of 0.47 % as 
compared to 0.32 - 1.56 % in other studies (6,8,9,12). The day-to-day variability was 
measured in healthy subjects after two different intervals. N o significant difference 
was found between both intervals. This implies that the day-to-day variability 
remains approximately the same, in spite of the length of the interval between the 
repeated measurements. Ch
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D ata of diurnal variability in leg volume have only been reported in healthy subjects. 
An increase of 1.2 % during the day was found in 12 subjects (9) and 2.4 % in one 
subject (10). In the present study we found a larger increase of 5.9 % in patients with 
peripheral oedema. T his is of clinical relevance w hen repeated volum etric 
measurements are performed for m onitoring purposes. Since a considerable diurnal 
variability in leg volume was found, one m ust consider that measurements should be 
performed at the same time of the day.
D iurnal differences were greater in volumetry than in ankle circumference, which can 
easily be explained by the fact that volumetry reflects a three-dimensional feature 
whereas the ankle circumference was measured two-dimensionally. The trends of the 
ankle circumference during the day were rather irregular, probably as a result of 
measuring the ankle circumference at only one level. The reason we used this method 
of calculation, instead of an advanced circumference calculation, is that this method 
is still widely used for monitoring peripheral oedema. We believe our results 
discourage the use of ankle circumference at one level, as a m onitoring tool.
The mean body weight remained the same during the day. D iurnal shifts between the 
extra- and intravascular com partm ent have no apparent effect on fluctuations in 
diuresis and body weight. The accuracy of our scale was 100 g. Small diurnal 
fluctuations in body weight could therefore no t be detected. However, it is debatable 
w hether such small fluctuations have any clinical relevance.
The response to treatm ent was obvious in all three parameters. The largest response 
was found in the data of the leg volume. The relationship between leg volume and 
body weight was poor, which suggests that the value of body weight as a tool for 
m onitoring oedema is limited.
Water-displacement volumetry is a simple tool, which enables accurate measuring of 
the leg volume. The m ethod can be used for m onitoring the course of a disease, such 
as heart failure, static oedema, thrombosis, renal disease or endocrine disorders, 
m onitoring the effect of treatm ent, such as diuretic therapy, or studies examining side 
effects of drugs, such as calcium channel blockers.
In summary, this study demonstrates 1) a high reproducibility of water-displacement 
volumetry, 2) a considerable diurnal variability in  the volume of the lower leg in 
patients w ith persisting peripheral oedema, and 3) a suitability of the method for 
m onitoring peripheral oedema.
Volumetric measurem ents o f  p eripheral oedema in  clin ica l conditions.
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Discontinuation of furosemide decreases arterial 
carbon dioxide tensions in patients with COPD
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4.1 Summary
The objective was to evaluate if the discontinuation of furosemide resulted in a 
decrease in  PaC O 2 and an increase in  daytime and nocturnal oxygenation. 
Furosemide is widely prescribed in patients w ith C O PD  for the treatm ent of 
peripheral edema. It is known that it causes a metabolic alkalosis. A diminished 
chemoreceptor stim ulation may cause a decreased alveolar ventilation.
Twenty patients w ith stable C O PD  [10 males, m edian (range) age 70 (58-81) years, 
FEVi 35 (19-70) % predicted] participated in a randomized, double-blind, placebo­
controlled, cross-over trial. Subjects were included if they had received furosemide 40 
mg daily for the treatm ent of peripheral edema for at least a m onth  and if they had 
a mean nocturnal SaO2<92%. Patients w ith cardiac left ventricular dysfunction, sleep 
apneas, and patients receiving other diuretics, ACE inhibitors, potassium or chloride 
replacement therapy, or long-term O 2 treatm ent were excluded. Furosemide was 
discontinued for 1 week and replaced by placebo in the first or the second week. 
Ventilation, daytime arterial blood gases and nocturnal SaO 2 were measured at 
baseline, after 1 and after 2 weeks. 16 subjects completed the study. Ventilation 
increased from 10.4 (6.7-15.4) at baseline to 11.6 (8.7-14.0) l/m in  after 
discontinuation of furosemide (p<0.05). PaC O 2 decreased from 6.0 (4.6-8.5) to 5.5 
(4.3-8.1) kPa (p). Daytime and nocturnal oxygenation did no t improve.
Although it does no t improve oxygenation, the discontinuation of furosemide 
decreases PaCO 2 in  patients w ith severe C O PD .
4.2 Introduction
Peripheral edema occurs in  a substantial num ber of patients w ith C O PD , especially 
in  those w ith hypercapnia and hypoxemia (1-3). Usually this is treated w ith loop 
diuretics. Loop diuretics induce a metabolic alkalosis by increasing urinary H+ loss 
due to secondary hyperaldosteronism and due to a contraction of the extracellular 
volume around a constant am ount of extracellular bicarbonate (4). The consequent 
metabolic alkalosis will cause a diminished chemoreceptor stim ulation (5,6) and, as 
a result, a reduced alveolar ventilation (7,8). The clinical relevance of a metabolic 
alkalosis in patients w ith C O PD  was already reported by Bear et al (9). In the 
described patients, blood gases and clinical symptoms benefited from the correction 
of metabolic alkalosis. However, this was an uncontrolled study and the initial 
metabolic alkalosis was due to several causes. The effect of loop diuretic induced 
alkalosis has only been described in animal studies. Furosemide was found to
o
decrease ventilation in young rabbits (10). The effect of loop diuretic induced alkalosis 
on ventilation in  patients w ith C O PD  has no t been studied yet. Moreover, no 
placebo controlled studies have been performed, evaluating the benefit of the 
correction of alkalosis in C O PD  patients. A decreased ventilation caused by loop 
diuretics may increase PaC O 2 . It is of clinical relevance to evaluate the potential 
increase in PaCO 2 due to loop diuretics, as hypercapnia is believed to be an ominous 
sign for m orbidity and mortality (11-13). A decreased ventilation could also decrease 
the oxygenation. This may be more pronounced at night, since hypoventilation is 
often seen during sleep in C O P D  (14-18). Loop diuretics may progress the level of 
hypoventilation during sleep and cause a further deterioration of the nocturnal 
hypoxemia. Furosemide, prescribed for peripheral edema, was discontinued in 
C O PD  patients w ith nocturnal hypoxemia in a double blind placebo controlled 
design. It was hypothesized that the discontinuation of loop diuretics would result in 
a decrease in  PaCO 2 and an increase in daytime and nocturnal oxygenation.
4.3 Materials and methods
4.3.1 Subjects
T he study was performed in 20 patients w ith C O PD , consisting of 10 males, w ith a 
median (range) age 70 (58-81) years, and a median (range) FEV 1 35 (19-70) % of 
predicted (19). Subjects were included if they had a stable course of the disease. 
C O PD  was defined according to the standards of the American Thoracic Society 
(20) and a stability of the disease as a fluctuation of FEV 1 less than 10% over the last 
6 m onths and an absence of exacerbations for at least 8 weeks prior to the study. 
Moreover, subjects were only included if they had received furosemide for the 
treatm ent of peripheral edema for at least a m onth. Subjects also needed to  have a 
mean nocturnal SaO2<92%, because a decrease in alveolar ventilation will cause a 
substantial fall in SaO 2 if the SaO 2/PaO 2 relationship lies on the shoulder or on the 
steep part of the oxygen saturation curve.
Subjects were excluded if they had a history of another pulm onary disease, left 
ventricular dysfunction, obstructive and/or central sleep apneas, or if they received 
long term oxygen, other types of diuretics, ACE inhibitors, potassium or chloride 
replacement therapy. O ther exclusion criteria were hypokalemia or hypovolemia, in 
order to rule out other causes of metabolic alkalosis. A left ventricular dysfunction 
was defined as an echoscopic left ventricular end diastolic diameter > 58 mm, and/or 
an end systolic diameter > 44 m m  and/or a moderate to severe valvular disease. As 
withdrawing diuretics may worsen the general condition of patients w ith cor
D iscon tin u ation  o f  furosem ide decreases arterial carbon dioxide tensions in  pa tients with C O P D
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pulmonale, subjects were also excluded right ventricular systolic pressure (RVSP) > 
35 m m H g. Subjects w ith a borderline increased RVSP between 30 and 35 m m H g 
were only included if they had no clinical signs of edema (n=3). A sleep apnea or 
hypopnea syndrome was defined as an apnea /  hypopnea index > 15 /hour (21). The 
study protocol was approved by the local hospital ethical committee. A signed and 
dated informed consent was obtained from all subjects.
4.3.2 Study design
Before the start of the study, all subjects received furosemide for the treatm ent of 
peripheral edema. This was then replaced by capsules, containing furosemide 40 mg, 
or identical capsules, containing placebo. A cross-over design was used, w ith a total 
duration of 2 weeks; 1 week furosemide and 1 week placebo, in random  order. 
Subjects visited the lung function laboratory at baseline, after 1 and after 2 weeks. In 
between, subjects measured their body weight daily at home. Subjects were 
instructed to contact the study investigator in case of an increase in body weight of 
more than 0.5 kg per day or in case of worsening of dyspnea. O ther medication 
remained unchanged during the study. Urine samples were obtained at each visit to 
check the compliance to study medication.
4.3.3 Measurements 
Selection phase
N octurnal SaO 2 was measured initially at home by pulse oximetry [8500M, N onin 
Medical Inc., Plymouth, M innesota, USA] by using a finger probe. SaO 2 values were 
stored in memory and processed afterwards software version [N N856 03/95, 
PROFO X  associates Inc., Escondido, California, USA]. Echocardiography was 
evaluated by the Power Vision apparatus [Toshiba Corporation Medical Systems 
Company, Tokyo, Japan]. The consecutive polysomnography in the hospital 
[Voyageur, Nicolet Biomedical Inc., Madison, Wisconsin, USA] consisted of 
electroencephalography (EEG), electromyography (EM G), electrooculography 
(EOG) measurem ents, airflow them istor [Infinity sensor 1450, New Life 
Technologies Inc., M idlothian, Virginia, USA) ], thoraco-abdom inal movements 
[1482, Pro-Tech Services Inc., Woodinville Washington, USA] and nocturnal SaO 2 . 
The sleep states were assessed manually (22).
D isco n tin u a tio n  o f  furosem ide decreases a rte ria l carbon d ioxide tensions in  p a tie n ts  w ith  C O P D  
Study phase
Measurements, performed at baseline, after 1 and after 2 weeks, consisted of lung 
function tests, arterial blood gas sampling, nocturnal oximetry w ith measurements of 
EEG, EM G  and EOG , measurements of body fluid homeostasis and collection of 
urine samples.
Tidal volume, breathing frequency and m inute ventilation were measured by 
spirometry [Pulmonet III, Sensormedics Corp., Yorba Linda, California, USA]. 
Variables were measured during 5 minutes, at the same tim e each day, in a quiet 
room, in supine position, after 15 minutes of rest and w ithout consum ption of 
coffee. The ventilatory response to  hypercapnia was tested under normoxic 
conditions by the steady-state method (23,24). Subjects were connected to a closed 
spirometry circuit, in which the carbon dioxide level could be increased by adjusting 
a 3-way valve, partially short-circuiting a C O 2 absorber in the inspiratory limb of the 
circuit. The increase in end-tidal carbon dioxide tensions was measured w ith a 
sampling capnograph [Multicap, Datex Instrum entarium  Corp., Helsinki, Finland]. 
M inute ventilation was measured simultaneously [Pulmonet III, Sensormedics 
Corp., Yorba Linda, California, USA]. The total transfer capacity for carbon 
monoxide (TLCO), and the TLC O  corrected for alveolar volume (KCO) were 
measured by the single-breath method [2450, Sensormedics Corp., Yorba Linda, 
California, USA] (25). T he respiratory muscle function  was evaluated by 
measurements of maximal in- and expiratory m outh  pressure (Pimax and Pemax) 
[microM PM, Sensormedics Corp., Yorba Linda, California, USA].
Arterial blood gas samples were obtained, under the same circumstances as during 
measurements of resting ventilation [IL 1620, Instrum ents Laboratory Corp., 
Milano, Italy]. The method for measuring bicarbonate was independent from that 
for PaC O 2 . The alveolar-arterial oxygen gradient was calculated, using the alveolar 
gas equation, assuming a R-value of 0.8.
Nocturnal oximetry was performed at home during the night preceding the visit, by 
means of the same portable pulse oximeter as during the selection phase. Subjects 
were instructed to switch the oximeter on and off at the same time each night, to 
match the recorded tim e during the nights. EEG, EM G and EO G  [Oxford Medical 
9000, Oxford Instrum ents Medical Systems, Abingdon, Oxfordshire, UK] were 
recorded to assess the quality of sleep. The level of nocturnal hypoxemia was 
evaluated by the mean SaO 2 , the time in hypoxemia (SaO2<90%) and the time in 
desaturation (SaO2>4% below baseline awake, defined as the first 5 m in of the 
recording). The variables were calculated for the entire night, the actual sleep and 
actual rapid eye movement (REM) sleep, providing a standardization for the stage of 
sleep. Ch
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Body weight was measured after voiding at the same tim e each visit [Seca 761, Vogel 
Halke, Hamburg, Germany]. The volume of the lower legs was calculated from the 
displacement of water after immersion of the feet in a standardized water bath (26). 
This method provides an accurate evaluation of differences in peripheral edema. 
Urine furosemide analysis was done qualitatively using high performance liquid 
chromatography and diode array detection.
Statistical analysis
The SPSS package, version 9.0 (SPSS Inc., Chicago, Illinois, USA) was used for 
statistical analysis. The Wilcoxon signed rank test was used to test differences 
between variables before and after discontinuation of furosemide. The Spearman 
correlation was used to  perform bivariate correlation analysis.
The decrease in PaC O 2 , after discontinuation of furosemide, was correlated to several 
baseline variables to determine if the outcom e of correcting alkalosis could be 
predicted. The next variables were chosen as these evaluate the level of alkalosis, the 
degree of respiratory failure, airway obstruction, chemoreceptor sensitivity and the 
ventilatory reserve respectively. A correlation was performed w ith blood gas values 
(pH, base excess, PaC O 2 , PaO 2 and daytime and nocturnal SaO 2). The ventilatory 
response to hypercapnia, FEV 1, respiratory muscle function and m inute ventilation 
as a fraction of the maximal voluntary ventilation. A p-value < 0.05 was considered 
significant. All results are expressed as median (range).
4.4 Results
4.4.1 Subjects
Sixteen subjects completed the study. Urine analysis showed a full compliance with 
respect to the study medication. O f the 4 subjects who did no t complete the study, 
1 had a weight gain of 3.5 kg after 4 days w ithout furosemide, associated w ith an 
increase in peripheral edema and worsening of dyspnea, 2 were no t willing to 
continue the study and 1 became unstable during the study. She developed terminal 
respiratory failure (FEV 1 29 % predicted, PaC O 2 8.2 kPa) aggravated by a pulm onary 
tract infection and died shortly after the study. She was in an end stage C O PD  and 
the death was unlikely associated w ith the withdrawal of furosemide.
O f the subjects who had a borderline increased RVSP, 1 did no t complete the study 
(the subject who developed terminal respiratory failure). The other 2 continued the 
study uncomplicated.
9
T he mean potassium level of the subjects who entered the study was 4.2 m m ol/l 
(range 3.5-4.8) at baseline.
4.4.2 Lung function tests
Discontinuation of furosemide caused an increase in m inute ventilation from 10.4 
(6.7-15.4) l/m in to 11.6 (8.7-14.0) l/m in (p<0.05). This could no t be derived from 
a significant increase in tidal volume or breathing frequency (table 1). The T L co 
and the K co could be measured in 9 (53%) subjects. The other subjects were no t able 
to perform the breath holding procedure. N o significant differences were found in 
the ventilatory response to hypercapnia, FEV 1, T L co and K co or P.max and Pemax 
(table 1).
D iscon tin u ation  o f  furosem ide decreases arterial carbon dioxide tensions in  pa tients with C O P D
n=16 On furosem ide Off furosem ide p-value
Ve, l/m in 10.4 (6.7-15.4) 11.6 (8.7-14.0) <0.05
Vt, l 0.70 (0.4-1.0) 0.73 (0.5-1.2) NS (0.12)
f, m in-1 16.5 (9-19) 16.5 (12-23) NS
FEV1, % predicted 38 (19-70) 41 (18-73) NS
FEV1/VC 48 (23-70) 45 (28-68) NS
HCVR, min-1.kPa-1 4.4 (0.4-11.2) 3.8 (0.9-10.4) NS
T L co, %  (n=9) 48 (28-71) 47(23-81) NS
Kco, % (n=9) 42 (36-79) 41 (24-101) NS
Pimax, kPa 4.2 (2.3-7.0) 5.5 (2.3-7.2) NS
Pemax, kPa 10.1 (2.5-18.4) 10.1 (2.5-18.4) NS
Table 1. Lung function tests. Results are expressed as median (range). Ve: M inute ventilation. Vt: Tidal volume. f: breathing 
frequency. FEV 1 : forced expiratory volume in 1 second. HCVR: Ventilatory response to hypercapnia. TLco! total diffusion capacity 
for carbon monoxide. Kco: TLco, corrected for alveolar volume. Pimax and Pemax: maximal in- and expiratory m outh pressures.
4.4.3 Blood gases and nocturnal oxygen saturation
An increased base excess and a pH  within norm al limits were found at baseline, as a 
reflection of a respiratory-compensated metabolic alkalosis. Correction of the 
alkalosis was confirmed by a significant decrease in the m edian base excess. The 
median PaC O 2 value decreased from 6.0 (4.6-8.5) kPa to 5.5 (4.3-8.1) kPa (p<0.01) 
(table 2). The individual values are presented in figure 1.
T he effect of 1 week reintroduction of furosemide could be evaluated in the subjects 
who had randomly received placebo in the first and furosemide in the second week 
(n=10). The PaC O 2 after 1 week reintroduction was 5.6 (5.2-8.5) kPa, as compared 
to 5.9 (5.2-8.4) kPa at baseline (NS, p=0.08) and 5.4 (4.9-8.1) kPa after 1 week of 
placebo (NS, p=0.15). This was associated by a BE of 3.7 (0.2-7.9) m m ol/l after 
reintroduction, as compared to 3.7 (0.1-7.9) m m ol/l at baseline (NS) and 1.8 (-0.5­
8.3) mm ol/l after placebo (p<0.05). Ch
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N o improvement in oxygenation was found. The alveolar-arterial oxygen gradient 
increased significantly from 3.5 (1.3-4.9) to 4.2 (1.7-5.1) kPa (p<0.05). The quality 
of sleep during the different nights was comparable (table 3), allowing a reliable 
comparison of nocturnal S a o 2 values during the different nights. No differences in 
the variables of nocturnal SaO 2 during the entire night were found (table 3). The 
same S a o 2 variables, determined for the actual sleep and for REM  sleep specifically, 
were also no t statistically significant on and off furosemide.
TO
on timnirUfl afThJiuariftfe
Figure 1. P a c o 2  before and after discontinuation of furosemide The thin lines represent individual subjects, the 
thick line the median values.
D iscon tin u ation  o f  furosem ide decreases arterial carbon dioxide tensions in  pa tients with C O P D
n=16 On furosem ide Off furosem ide p-value
pH 7.42 (7.36-7.48) 7.40 (7.37-7.42) NS
BE, m m ol/l 4.0 (0.1-8.7) 1.8 (-1.9-8.3) <0.01
PaCÜ2 , kPa 6.0 (4.6-8.5) 5.5 (4.3-8.1) <0.01
PaÜ 2 , kPa 8.8 (5.7-10.7) 8.7 (6.2-10.4) NS
SaÜ 2 , % 91.5 (73.6-95.3) 92.1 (78.3-94.1) NS
A-a g radient, kPa 3.5 (1.3-4.9) 4.2 (1.7-5.1) <0.05
Table 2.
Daytime blood gas values. Results are expressed as median (range) values of the whole group. BE: base excess. A-a gradient: alveolar-
arterial oxygen gradient.
n=16 On furosem ide Off furosem ide p-value
Quality o f sleep
Recorded tim e, min 471 (341-642) 467 (305-576) NS
Fraction of s leep  during  night, % 70.8 (41-93) 80.0 (46-89) NS
Sleep sta te s  during  sleep, %
Non-REM sleep, I + II 68.5 (60-90) 71.6 (60-90) NS
Non-REM sleep, III + IV 14.2 (0-29) 9.8 (0-17) NS
REM sleep 17.7 (10-28) 18.5 (10-23) NS
SaO2 variables, en tire  n ight
Baseline aw ake, % 92.5 (75-96) 93.0 (77-95) NS
M ean SaÜ 2 , % 90.0 (72-93) 90.6 (71-93) NS
Time sp e n t in hypoxia, % 33.6 (4.5-100) 21.6 (0.6-100) NS
Time sp e n t in desa tu ra tion , % 20.2 (0.6-90.9) 21.3 (0.6-68.6) NS
Lowest SaÜ 2 , % 74.5 (40-86) 71.0 (40-88) NS
Table 3. Quality of sleep and nocturnal SaO 2 .Results represent median (range) values of the whole group. Baseline awake: first 
5 minutes of recording. Hypoxia: Sa02<90%. Desaturation: SaO2>4% below baseline awake.
4.4.4 Body fluid homeostasis
The body weight increased from 74.0 to 74.5 (0-3.0) kg (p<0.05). The increase 
could be attributed to 5 (31%) of the 16 subjects in whom an increase in  body 
weight was found w ith a range of 1.0—3.0 kg. The median leg volume increased from 
2609 (2067-2948) to  2632 (2037-3036) ml (p<0.01).
4.4.5 Predictors for response to correction o f alkalosis
N o significant correlation was found between the decrease in P a c o 2 and baseline 
variables, including blood gas values, ventilatory response to hypercapnia, FEV 1, 
Ventilation /  maximal voluntary ventilation, Pimax or Pemax.
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4.5 Discussion
The discontinuation of furosemide, prescribed for peripheral edema in  stable C O PD  
patients w ith a mean nocturnal S a o 2 below 92%, resulted in an increased minute 
ventilation and a decrease in PaC O 2 . This was no t associated w ith an increase in 
daytime or nocturnal oxygenation.
The increased base excess, accompanied by a norm al pH , confirms a respiratory- 
compensated metabolic alkalosis at baseline. The correction of the alkalosis, due to 
the withdrawal of furosemide, resulted in a decrease in the median PaC O 2 of 0.5 kPa. 
Because no significant correlations were found between the baseline blood gas values 
or between other variables, reflecting respiratory failure, chemoreceptor sensitivity, 
the ability to generate ventilatory reserve, and the decrease in PaC O 2 , baseline 
characteristics, predicting the benefit of correction of alkalosis, could no t be 
determined.
Apart from the effect on the metabolic acid-base status, furosemide also lowers the 
plasma potassium levels. Some investigators (27) hypothesized that potassium will 
also stimulate ventilation via peripheral chemoreceptors. Consequently, stopping 
furosemide might increase the serum plasma levels and thus stimulate ventilation. 
O n  the other hand, our group has brought forward experimental evidence that serum 
plasma levels are no t very relevant in the control of breathing of C O PD  patients (28), 
confirming the work of others in resting norm al subjects (29). At the start of the 
study, we had established that serum plasma levels were within the normal range. 
Thus, it is no t really possible to separate supposed effects of change s in fixed acid or 
in  potassium on the control of breathing in our patient group. Irrespective the 
mechanism, ventilation increases and PaC O 2 decreases after stopping furosemide in 
patients w ith C O PD .
The daytime and nocturnal oxygenation did no t improve after the discontinuation 
of furosemide. The oxygen diffusion capacity may have decreased, due to retention 
of pulm onary interstitial fluid in the absence of diuretic therapy. If so, this is 
interesting because patients w ith cardiac failure were excluded explicitly in our study. 
A decrease in diffusion capacity was no t apparent from the transfer capacity for 
carbon monoxide, bu t these measurements could only be performed in 53% of the 
subjects. A worsened ventilation-perfusion mism atch may also have occurred, for 
example due to a lower functional residual capacity w ith airway compression, 
reduced airway clearance or bronchial wall thickening. The lung function tests, 
however, showed no significant changes. A combination of factors was probably 
present in the individual subjects. The ventilatory response to hypercapnia was low
in these subjects, implying a low chemoreceptor sensitivity. This could explain why 
the differences in ventilation and in PaC O 2 were rather low in some of the subjects. 
Therefore, only a marginal advantageous effect on the oxygenation may have 
occurred in  some subjects, which was easily counteracted by a worsening in diffusion 
capacity and/or ventilation-perfusion mismatch. The slight increase in alveolar- 
arterial oxygen gradient suggests a worsened diffusion capacity for oxygen and/or a 
worsened ventilation-perfusion mismatch. However, it needs to be noted that the 
used equation has a major shortcoming because a fixed R-value of 0.8 was assumed. 
In  fact, the R-value may have changed as the level of PaC O 2 was unequal in both 
situations.
T he discontinuation of furosemide had no statistically significant effect on the 
ventilatory response to hypercapnia or the respiratory muscle function, bu t it needs 
to be remarked that the sample size (n=16) may have been too small to detect small 
effect.
Subjects were cardiac screened before selected to enter the study, to rule out the risk 
of heart failure in absence of furosemide. The study can therefore no t be used to 
estimate the safety of discontinuing loop diuretics in patients w ith C O PD  in general. 
An increase in  peripheral edema was found, which was no t surprising as furosemide 
was prescribed for the treatm ent of peripheral edema. However, it is interesting to 
note that only a marginal increase in peripheral edema was found, suggesting that the 
increase was of statistical bu t no t of clinical relevance. The extra vascular fluid 
retention, shown by the increase in the lower leg volume, was no t necessarily 
accompanied by an increase in body weight. In a previous study, we already found a 
poor correlation between peripheral edema and body weight (26). A shift between 
the intra- and the extra-vascular com partm ent may have occurred, accompanied by 
a total am ount of body fluid that remained equal.
T he results are in agreement w ith previous studies, demonstrating hypoventilation in 
response to metabolic alkalosis (7,8). N o relationship between metabolic alkalosis 
and hypoventilation was found in other studies (30), bu t this can probably be 
explained by an inappropriate induction of the alkalosis, or to a higher degree of 
ventilation due to  stress, fever, infection or pre-existing tachypnea (8). A clear 
ventilatory benefit after correction of alkalosis was found in our group of C O PD  
patients. This was reported earlier, bu t only in  an uncontrolled study, evaluating 
alkalosis of various origins (9). The present results showed no statistically significant 
correlations between baseline blood gas values and the decrease in  PaC O 2 . Earlier 
studies in hum ans already showed a wide 95%  confidence interval in P C O 2 in 
response to  increased bicarbonate levels (31). Moreover, the ventilatory response to
D iscon tin u ation  o f  furosem ide decreases arterial carbon dioxide tensions in  pa tients with C O P D
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metabolic alkalosis may be even harder to examine in disorders associated with 
hyperventilation (8). It seems that patients, who will benefit from the correction of 
alkalosis, are difficult to recognize.
It was already noted that hypoventilation in response to metabolic alkalosis has 
serious implications in patients w ith high PaC O 2 and low PaO 2 (8,9). C O PD  
patients w ith a tendency towards hypercapnia require extra attention, as hypercapnia 
is believed to be an ominous sign for m orbidity and mortality (11-13). Moreover, the 
increased level of PaC O 2 due to furosemide may cause an increased tendency towards 
fluid retention, which may counteract the diuretic effects of furosemide. The increase 
in  PaC O 2 is of clinical relevance, especially if it is taken into consideration that loop 
diuretics are prescribed in  a substantial num ber of C O PD  patients and usually for a 
long period of time. If there is an indication for diuretic therapy in a C O PD  patient, 
other types of diuretics need to be considered. Spironolacton, causing no acid /  base 
shift, or acetazolamide, causing a metabolic acidosis, could be better alternatives. 
Acetazolamide could counteract the metabolic alkalosis and may be beneficial as 
single therapy or in addition to  loop diuretics (32).
The effect of reintroduction of furosemide for 1 week could be evaluated in the 10 
subjects who had random ly received placebo in the first and furosemide in the second 
week. As expected, the PaC O 2 increased after reintroduction, bu t it did no t reach the 
baseline level. Although this difference did no t reach statistical, it could suggest that 
if given longer even higher increases in PaC O 2 could be seen. However, it needs to 
be remarked that this was observed in  only a small num ber of subjects.
In conclusion, this study shows that the discontinuation of furosemide, prescribed 
for the treatm ent of peripheral edema, lowers arterial carbon dioxide tensions in 
patients w ith C O PD .
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C hapter 5
Effect of acute metabolic acid/base shifts on 
the human airway calibre.
Folkert Brijker1,2, Frank JJ van den Elshout2, Yvonne F Heijdra3,
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5.1 Summary
Acute metabolic alkalosis (NaHCO3), acidosis (N H £ l) , and placebo (NaCl) were 
induced in  15 healthy volunteers [12 females, m edian age 34 (range 24-56) years] in 
a double blind, placebo controlled study to evaluate the presence of the effects on 
airway calibre. Acid-base shifts were determined by capillary blood gas sampling. 
Measurements were performed at the maximal acid-base shift, 90 m in after 
intervention. Airway resistance (Raw) and specific airway conductance (sG.w), were 
evaluated, as primary variables, pre and post intervention. Secondary variables, 
including bronchial responsiveness to histamine, maximal respiratory m outh 
pressures and grip strength, were evaluated post intervention.
In alkalosis, base excess (BE) increased from -0 .3  (-3.0-1.9) to 3.0 (1.0-4.8) m m ol/l 
and pH  increased from 7.41 (7.37-7.43) to 7.44 (7.39-7.47) (both p<0.01), 
accompanied by an increase in PaCO2: 4.7 (4.0-5.7) to 5.0 (4.7-6.1) kPa (p<0.05). 
R,w increased from 0.156 (0.134-0.263) to 0.169 (0.132-0.271) kPa.s/l (p<0.05), 
sGaw decreased, bu t this was no t statistically significantly. In acidosis, BE decreased 
from -0.2 (-2.0-2.2) to -3 .5  (-6.3-1.1) m m ol/l and pH  decreased from 7.41 (7.39­
7.45) to 7.36 (7.31-7.40) (both p<0.01), accompanied by a non-significant decrease 
in  PaCO 2. Changes in  Raw and sGaw were contrary to those in alkalosis, bu t did not 
reach statistical significance.
Acute metabolic acid-base shifts mildly influence the airway calibre in healthy hum an 
subjects.
5.2 Introduction
Hypocapnic hyperventilation causes bronchoconstriction (1-3), due to contraction 
of bronchial sm ooth muscles (4). O n  the contrary, hypercapnic hypoventilation has 
been shown to cause bronchodilatation (2). C O 2. effects seem to be related to altered 
activity of contractile elements (4,5), bu t also seem to influence receptor binding to 
bronchial agonists (6,7) and to mediate the vagal nerve system (8). The effect on the 
contractile elements may be ascribed to pH  related changes. Low pH  causes a 
decreased cellular influx of calcium, reduces the affinity of troponin for calcium, 
increases the calcium binding to the sarcoplasmatic reticulum and may reduce the 
rate of glycolysis and thus ATP resynthesis (9,10). These pH  related effects suggest 
that metabolic acid-base shifts influence the contractility of muscles. Earlier studies 
have shown that metabolic acidosis decreases the strength of striated muscle types, 
such as diaphragm (11), myocardial muscles (12) and skeletal muscles (13). The 
0
effects of acute metabolic acid-base shifts on contractility of bronchial sm ooth muscle 
were investigated in an in  vitro study by Duckles (4), by evaluation of isolated feline 
bronchial rings. A changing pH , w ith constant C O 2., mimicked the effect of primary 
C O 2 . changes. In an other study in anaesthetised dogs, isocapnic acidosis (by infusion 
of HCl) was equal to hypercapnic acidosis (by inhalation of C O 2.) in its ability to 
inhibit bronchoconstriction (6). To date, there have been no clinical evaluations of 
the effects of metabolic acid-base shifts on the hum an airway.
It was hypothesised that acute metabolic acidosis w ould lead to bronchial dilatation, 
whereas alkalosis was hypothesised to cause bronchial constriction. The primary aim 
of this study was to  evaluate the presence of the effects of acute metabolic acid-base 
shifts on the airway resistance and conductance. As secondary endpoints, the 
bronchial responsiveness to histamine was measured, because an underlying tendency 
towards bronchial constriction can lead to an increased bronchial responsiveness 
(14). In addition, the respiratory and peripheral skeletal muscle strength were also 
evaluated to determine the effect on striated muscles types.
5.3 Methods
5.3.1 Subjects and design
A double blind placebo controlled study was conducted in a group of 15 healthy 
subjects (12 females) w ith a median age of 34 (range 24-56) years. Subjects were 
excluded if they had a history of asthma, other pulm onary disease or allergic rhinitis 
or if they had suffered from an respiratory tract infection during the 8 weeks prior to 
the study.
All subjects were subjected to induced alkalosis, induced acidosis and 2 sessions of 
placebo, in random  order. Each intervention was performed on 1 day, w ith an 
interval of at least 3 days between intervention days to eliminate effects of the 
previous intervention on the measurements. Placebo was administered twice to assess 
the reproducibility of the measured variables.
T he study protocol was approved by the local hospital ethical committee. A signed 
and dated informed consent was obtained from all subjects.
5.3.2 Interventions
Metabolic acid-base changes were induced by the ingestion of fluid, containing 
am m onium  chloride to achieve acidosis, or sodium bicarbonate to achieve alkalosis. 
Placebo consisted of ingestion of saline. Goal was to evaluate a change in  base excess 
(BE) of at least 2 mm ol/l. The required amounts were calculated as follows (15):
E ffect o f  acute m etabolic acid/base shifts on the hum an airw ay calibre.
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- Ammonium chloride containing fluid (ml): (delta BE * molecular weight of 
am m onium  chloride * fraction of extracellular fluid * body weight) /  
(Cam m onium  chloride of ingested fluid) = (2 * 53.5 * 0.3 * body weight) /  60 =
0.535 * body weight (kg).
- Sodium bicarbonate containing fluid (ml): (delta BE * molecular weight of 
bicarbonate * fraction of extracellular fluid * body weight) /  (C bicarbonate of ingested 
fluid) = (2 * 61.0 * 0.3 * body weight) /  61 = 0.60 * body weight (kg).
The calculated portion was ingested twice, at t = 0 and at t = 60 min, w ith variables 
measured at t  = 90 m in (15).
5.3.3 Measurements
Arterialised capillary blood gas sampling were obtained to  determine the induced 
acid-base shifts.
The primary variables, airway resistance (Raw) and specific airway conductance (sG.w), 
were measured by body plethysmography [6200, Sensormedics Corp., Yorba Linda, 
California, USA]. R™ was calculated as the slope of the pressure-volume loop 
between the first 0.5 l of the in- and expiratory volume and sG.w as the inverse ratio 
of R,w, corrected for the thoracic gas volume (Vtg). Afterwards, spirometry was 
performed, using the same apparatus.
Secondary variables consisted of the following. The respiratory muscle strength was 
measured as maximal in- and expiratory m outh pressure, sustained for at least 1 
second (P.max and Pemax) [microMPM, Micromedical Ltd., Chatham , Kent, UK] 
(16). The peripheral skeletal muscle function was assessed by grip strength 
dynamom etry (Pgnp) [Grip-A, Takei Scientific Instrum ents Inc., Tokyo, Japan]. The 
bronchial responsiveness to histamine was measured according to ERS criteria (17), 
using a maximal dose of provocation of 32 mg/ml. The usually evaluated provocative 
concentration causing a 20% decline in FEV 1 (PC 20) could no t be determined, as this 
decline was no t likely to occur consistently in  these healthy subjects. Instead, results 
were expressed as the concentration of histamine causing a 10% decline in FEV 1 
(PC 10). In  case of a less than 10% decline at the maximum provocative concentration, 
PC 10 was calculated by extrapolation of the dose-response curves, no t exceeding twice 
the maximum dose allowed (18).
Serum calcium, albumin, sodium, potassium and creatinin were determined, because 
abnormalities could potentially influence the results.
5.3.4 Statistics
The SPSS package, version 9.0 (SPSS Inc., Chicaco, Illinois, USA) was used for 
statistical analysis. Since the values were no t normally distributed, non-parametric 
®
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tests were used. p-value < 0.05 was considered significant, all p-values below 0.20 are 
presented as true values. All results are expressed as median (range).
Raw, sGaw, Vtg and FEV 1 were evaluated pre and post intervention on the same day. 
Differences w ithin the day were tested by the Wilcoxon signed rank test. P C 10, Pimax 
and Pemax and Pgrip were measured post intervention each day. Differences in baseline 
values between days were compared by non-parametric analysis of variance. 
Spearman correlation was used to  perform analysis of delta BE versus delta Raw and 
delta sG.w (alkalosis + acidosis), to determine the dose-response relationship between 
acid-base shifts and alterations in airway calibre.
T he coefficients of variation were calculated within the first placebo day for Raw, sGaw 
and FEV 1 and between both placebo days for P C 10, Pimax and Pemax and Pgrip for each 
subject. The reproducibility of the variables was assessed by calculating the mean of 
all individual coefficients of variation, defined as [SD /  mean] x 100%.
5.4 Results
5.4.1 Metabolic alkalosis
T he base excess (BE) increased from -0 ,3  (-3.0-1.9) to 3.0 (1.0-4.8) m m ol/l 
(p=0.001) and pH  from 7.41 (7.37-7.43) to 7.44 (7.39-7.47) (p=0.003). This was 
accompanied by an increase in PaC O 2 from 4.7 (4.0-5.7) kPa to 5.0 (4.7-6.1) kPa 
(p=0.014) (Table 1). O ther laboratory values (serum calcium, albumine, sodium, 
potassium and creatinin) remained within the norm al range.
R,w increased from 0.156 (0.134-0.263) kPa.s/l to 0.169 (0.132-0.271) kPa.s/l 
(p=0.033). sGaw decreased slightly, though the change was no t statistically significant 
(p=0.088) (Table 2). N o significant change in thoracic gas volume was found. The 
individual trends in BE, PaC O 2 , Raw and sG.w are presented in Fig 1a-d. No 
significant changes were found in Pimax, Pemax, Pgrip and P C 10, (Table 3).
Placebo day 1 Placebo day 2 Alkalosis day Acidosis day
pH, pre 7.41 (7.38-7.44) 7.41 (7.34-7.44) 7.41 (7.37-7.43) 7.41 (7.39-7.45)
pH, post 7.41 (7.36-7.43) 7.41 (7.36-7.43) 7.44 (7.39-7.47)** 7.36 (7.31-7.40)**
BE, pre (mmol/l) 0.10 (-3.0-2.3) -1.10 (-2.8-2.6) -0.30 (-3.0-1.9) -0.20 (-2.0-2.2)
BE, post (mmol/l) -0.70 (-2.9-1.8) -0.60 (-2.4-3.4) 3.00 (1.0-4.8)** -3.50 (-6.3-1.1)**
PaCÜ2, pre (kPa) 4.60 (4.3-6.0) 4.80 (4.1-6.1) 4.70 (4.0-5.7) 5.00 (4.2-5.5)
PaCÜ2, post (kPa) 4.80 (4.5-5.6) 4.90 (4.2-6.1) 5.00 (4.7-6.1)* 4.80 (3.9-5.5)
Table 1. Capillary blood gas values pre and post intervention Values are presented as median (range). BE: base excess. Statistical 
analysis was performed between pre and post intervention values: * p<0.05, ** p<0.01. The baseline values were not significantly 
different between days.
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5.4.2 Metabolic acidosis
The base excess (BE) decreased from -0 .2  (-2.0-2.2) to -3 .5  (-6.3-1.1) m m ol/l 
(p=0.001) and pH  from 7.41 (7.39-7.45) to 7.36 (7.31-7.40) (p=0.001). The 
median PaC O 2 decreased, bu t this was no t statistically significant (Table 1). O ther 
laboratory values (serum calcium, albumine, sodium, potassium and creatinin) 
remained within the norm al range.
The changes found during acidosis were contrary to those found during alkalosis; 
sG.w increased slightly, though the change was no t statistically significant (p=0.096). 
R,w decreased bu t no t statistically significant. The thoracic gas volume did no t change 
significantly (table 2). The individual trends in BE, PaC O 2, R,w and sG.w are 
presented in Fig 2a-d. N o significant changes were found in Pimax, Pemax, Pgrip and 
P C 10 (Table 3).
The delta BE ranged from -5 .0  - 4.8 mm ol/l (acidosis and alkalosis). W hen analysing 
delta BE versus delta R,w or delta sG.w, weak correlation’s were found, no t reaching 
statistical significance (delta BE versus delta Raw: r = 0.24, p = 0.19, delta BE versus 
delta sGaw: r = -0.31, p = 0.10).
5.4.3 Reproducibility o f the measured variables.
The mean coefficients of variation of R.w, sG.w and FEV 1 w ithin the day were 8.2, 7.2 
and 1.5 % respectively. For Pimax and Pemax, and Pgrip, the mean coefficients of 
variation between days were 8.1, 4.5, and 3.6 % respectively. The largest coefficient 
of variation was found between days for P C 10: 28.5 %. However, this did no t exceed 
one dose step.
Placebo day 1 Placebo day  2 Alkalosis day Acidosis day
Raw, pre (kPa.s/l) 0.162 (0.098-0.228) 0.150 (0.132-0.218) 0.156 (0.134-0.263) 0.171 (0.134-0.251)
Raw, post (kPa.s/l) 0.174 (0.122-0.227) 0.159 (0.122-0.198) 0.169 (0.132-0.271)* 0.160 (0.125-0.280)
sGaw, pre (1/kPa.s) 1.87 (1.08-3.16) 1.96 (1.14-2.84) 1.90 (1.20-2.63) 1.69 (1.25-2.36)
sGaw, post (1/kPa.s) 1.79 (1.36-2.91) 2.04 (1.41-2.91) 1.69 (1.14-2.68) 1.78 (1.15-2.87)
Vtg, pre (l) 3.20 (2.52-5.47) 3.27 (2.57-4.80) 3.38 (1.97-4.51) 3.08 (2.32-4.63)
Vtg, post (l) 3.16 (2.30-5.03) 3.23 (2.31-4.77) 3.09 (2.29-4.48) 3.04 (2.27-4.56)
FEV1, pre (l) 3.39 (2.59-5.40) 3.31 (2.59-5.33) 3.31 (2.58-5.23) 3.36 (2.71-5.18)
FEV1, post (l) 3.42 (2.60-5.54) 3.38 (2.60-5.62) 3.32 (2.62-5.49) 3.43 (2.64-5.18)
Table 2. Raw, sGaw and FEV 1 , pre and post intervention. Values are presented as median (range). Ra«: Airway resistance, sGaw specific 
airway conductance, FEV 1 : forced expiratory volume 1n 1 sec. Statistics: values were compared pre and post intervention. * p<0.05. 
Baseline values differed not significantly between days.
o
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Figure la -d . Base excess, PaCCX R** and sGa«, pre and post induction of alkalosis.The th in  lines represent individual 
values, the thick lines the median of the whole group. Raw: airway resistance, sGaw: specific airway conductance.
Placebo day 1 Placebo day 2 Alkalosis day Acidosis day
Pmax, kPa 85 (55-151) 96 (52-154) 92 (55-169) 101 (54-146)
Pemax, kPa 131 (88-245) 142 (93-246) 128 (79-240) 139 (99-233)
Pgrip, KgF 36 (29-77) 37 (31-73) 36 (31-75) 36 (29-68)
PC10, mg/ml 13.0 (5.2-26.0) 10.3 (4.5-28.2) 17.3 (8.0-63.1) 13.1 (5.2-39.8)
Table 3. Muscle function tests and bronchial responsiveness to histamine. Values are presented as median (range). Pimax: maximal 
inspiratory m outh pressure, Pemax: maximal expiratory m outh pressure, Pgrip: maximal grip strength, PC 1 0 : Concentration of 
histamine causing a 10% fall in FEV 1 . Statistical comparison of variables between different days showed no significant differences.
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Figure 2a-d. Base excess, PaCO 2 , Raw and sGaw, pre and post induction of acidosis.The thin lines represent individual 
values, the thick lines the median of the whole group. R w: airway resistance, sG**: specific airway conductance.
5.5 Discussion
This study shows the effects of acute metabolic acid-base changes on the airway 
calibre in healthy volunteers. Acute metabolic alkalosis caused an increase in airway 
resistance. The specific airway conductance decreased, bu t this was no t statistically 
significant. Similar results in opposite direction were found in acidosis, though these 
were no t statistically significant. N o significant effects were found on respiratory or 
peripheral skeletal muscle function or bronchial responsiveness to histamine.
The changes in airway resistance and conductance are in agreement w ith the 
hypothesis that metabolic acid-base shifts can influence the hum an airway calibre, 
»
although no t all changes were found to be statistically significant. The induced pH  
shifts ranged from 7.36 to 7.44. The fact that a similar degree of acidosis proved to 
inhibit bronchoconstriction in  a previous study (6) implies that the interventions 
should be adequate to influence the airway calibre. It is likely that the hypothesised 
effect is present, bu t only of small clinical importance. The lack of statistical 
significance in some of the results may be explained by the relatively small size of the 
group. In  order to determine the inter individual dose-response relationship between 
acid-base shifts and alterations in  airway calibre, the delta base excess (with a total 
range of 9.8 mmol/l) was correlated to  delta airway resistance and delta conductance. 
Only weak (not statistically significant) correlation’s were found, suggesting that 
clinically relevant changes in airways may only be observed in more severe acid-base 
disorders.
It is interesting to note that the statistically significant difference in  airway resistance 
in alkalosis was no t accompanied by a statistically significant difference in specific 
airway conductance, i.e. the inverse of airway resistance with correction for thoracic gas 
volume. This implies that an increase in airway resistance was partially due to a fall in 
the functional residual capacity. This may possibly be a result of a lower ventilatory 
drive. The increase in PaC O 2 after induction of alkalosis, indicates relative 
hypoventilation. Although a lower ventilatory drive is certainly compatible w ith a 
lower tonic activity of the respiratory muscle system, this could no t be confirmed, as 
no significant changes in thoracic gas volume were found.
Acute metabolic acid-base shifts had a statistically significant, bu t small effect on 
airway calibre in healthy subjects. This may be explained as follows. In acidosis, a 
further dilatation of airways may no t easily be achieved, because of the normal resting 
tone of sm ooth airway muscles. Although some bronchodilatation was demonstrated 
in healthy subjects, w ith for example anticholinergic drugs (19), it is reasonable to 
believe that a constriction of airways is easier to achieve than further dilatation. 
Effects may also have been counteracted by responsive C O 2 changes. Hypercapnia 
causes airway dilatation, whereas hypocapnia causes airway constriction (2). In this 
study, the responsive rise in PaC O 2 in alkalosis may have caused an airway dilatation, 
partly counteracting the airway constriction due to metabolic alkalosis. A decrease in 
PaC O 2 could be expected in metabolic acidosis. A decrease was found, bu t this was 
no t statistically significant. Since the potency of ventilatory response in  metabolic 
alkalosis and acidosis is normally equal (20), the lack of significance could be due to 
circumstantial factors.
In  contrast to the almost immediate ventilatory response to  metabolic acid-base 
disorders, there is a certain delay in metabolic response to ventilatory acid-base shifts.
E ffect o f  acute m etabolic acid/base shifts on the hum an airw ay calibre.
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This may explain why previous studies demonstrate clear effects of C O 2 changes on 
airway calibre. Moreover, primary respiratory acid-base shifts may have greater 
im pact because C O 2 readily passes the cellular membrane, while fixed ions depend 
on pum p mechanisms. Furthermore, C O 2 can have associated effects, such as 
influencing receptor binding to  bronchial agonists (6,7) and mediating the vagal 
nerve system (8).
The induced acid-base shifts had no significant effect on striated muscle function, 
assessed by respiratory muscle strength and grip strength. Data of the effect of 
acidosis on striated muscles in humans are relatively controversial. Contractility of 
the diaphragm was found to  decrease during hypercapnia by Juan (9), bu t this was 
no t found by M ador (21), even though the level of respiratory acidosis was more 
severe. However, it should be noted that the methods, used in  this study to assess 
striated muscle function, are rather insensitive to detect small effects.
The reproducibility of the evaluated variables was w ithin acceptable limits. The only 
variable showing a rather large coefficients of variation was P C 10, probably because a 
decline of only 10% in FEV 1 was evaluated. The usually measured PC 20 could no t be 
determined, because a 20% decline in FEV 1 could no t be determined in  these healthy 
subjects w ith an acceptable dose of the provocative agent. Although the variability 
did no t exceed one dose step, differences in the threshold due to the intervention may 
have remained undetected.
The present study is of clinical relevance because many conditions are associated with 
metabolic acid-base disorders. A depressing effect of metabolic alkalosis on airway 
calibre may have more pronounced clinical im pact in patients w ith obstructive 
pulm onary diseases and bronchial hyperresponsiveness. The marginal effects, 
although statistically significant, suggest that a physiological influence of acid-base 
shifts on airway calibre is present, bu t has no major clinical impact. However, since 
the given interventions were evaluated in healthy volunteers, the present data are not 
directly applicable to severe acid-base disorders or to  patients w ith obstructive 
pulm onary diseases or bronchial hyperresponsiveness.
In conclusion, m ild effects of acute metabolic acid-base shifts on airway calibre 
appear to be present in healthy volunteers.
E ffect o f  acute m etabolic acid/base shifts on the hum an airw ay calibre.
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Airway calibre in patients with asthma or COPD 
in acute metabolic acid/base shifts.
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6.1 Summary
Acute respiratory acid-base shifts are known to act on the airway calibre. This study 
sets ou t to investigate whether acute metabolic acid base shifts also alter the 
contractility of bronchial sm ooth muscles. Alkalosis was hypothesised to cause 
bronchoconstriction and acidosis to cause bronchodilatation, in patients w ith asthma 
or C O PD .
N ineteen subjects participated in a double blind, placebo controlled trial. The group 
consisted of 12 asthma patients (8 F, mean age 39 (±SD 12) years, FEV 1 93 (±9) % 
predicted, PC 20 1.9 (±1.0) mg/ml) and 7 C O PD  patients (3 F, age 60 (±8) years, 
FEV 1 54 (±15) %). Subjects ingested calculated amounts of bicarbonate (alkalosis), 
am m onium  chloride (acidosis), saline (placebo) or a tablet furosemide 40 mg 
(diuretic induced alkalosis), in random  order, each on a separate day. Shifts in base 
excess (BE) were determined by arterialised capillary blood gases. Changes in airway 
resistance (Raw), specific airway conductance (sGaw), FEV 1 and PEF were measured as 
primary variables. PC 20 was measured as secondary variable in asthma.
In acidosis, BE decreased from -0.4 (±1.3) to -4.2 (±1.4) m m ol/l (p<0.01), sG.w 
increased (all subjects) from 0.90 (±0.4) to 1.00 (±0.4) 1/kPa.s and PEF increased 
from 6.90 (±2.2) to 7.15 (±2.1) l/sec respectively (both p<0.05).
In alkalosis, BE increased from +0.5 (±1.3) to +3.8 (±1.5) m m ol/l (p<0.01), bu t no 
statistically significant changes in primary variables were observed. W hen evaluating 
the entire range of acid-base shifts, statistically significant correlation’s were found 
between the delta BE and delta FEV 1 (r=-0.37, p<0.05), delta Raw (r= +0.39, p<0.05) 
and delta PEF (r=-0.45, p<0.01). PC 20 did no t change.
Acute metabolic acid-base shifts have a moderate effect on the airway calibre of 
patients w ith asthma or C O PD .
6.2 Introduction
T he bronchial diam eter is influenced by P aC O 2 . H ypocapnia causes 
bronchoconstriction [1-3], while hypercapnia leads to bronchodilatation [3]. These 
effects are ascribed to changes in  the contractility of the bronchial sm ooth muscles, 
and may be due to underlying pH  shifts [4;5]. This can be explained as follows. Low 
pH  causes a decreased cellular influx of calcium, a reduced affinity of troponin for 
calcium, an increased calcium binding to the sarcoplasmatic reticulum and a reduced 
rate of glycolysis [6;7]. Metabolic acid-base shifts could therefore also influence the 
contractility of bronchial sm ooth muscles and the bronchial diameter. In a previous 
study, we investigated the effects of acute metabolic acid/base shifts on the airway
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calibre in  healthy volunteers [8]. Metabolic alkalosis increased the airway resistance. 
T he results in acidosis were in opposite direction of those in alkalosis, bu t these were 
no t statistically significant. Apparently, a constriction of airways could easier be 
achieved than a further relaxation in normal subjects, probably because of the normal 
resting tone of the bronchial sm ooth muscles. To date, no studies have evaluated such 
effects in patients w ith asthma or C O PD .
Acidosis was hypothesised to cause relaxation of sm ooth muscles, resulting in 
bronchodilatation and alkalosis was hypothesised to cause bronchoconstriction. The 
primary aim of this study was to evaluate the effects of acute metabolic acid-base 
shifts on the airway resistance (Raw), specific airway conductance (sG.w), forced 
expiratory flow in 1 second (FEV 1) and peak expiratory flow (PEF). Acidosis and 
alkalosis were induced by giving the subjects calculated amounts of am m onium  
chloride and bicarbonate. Furthermore, the im pact of furosemide was evaluated, as 
this frequently prescribed drug can also cause a metabolic alkalosis [9]. The 
secondary endpoint was to measure the bronchial responsiveness to histamine (PC 20), 
because alterations in the underlying tendency towards bronchial constriction may 
also lead to an increased bronchial responsiveness [10].
6.3 Methods
6.3.1 Subjects and design
A double blind placebo controlled study was conducted in a group of 19 subjects. 
T he intervention fluids and tablets, causing acid-base shifts, or placebo were 
administered on separate days in random  order and were no t traceable by the 
investigator and subjects. The asthma group consisted of 12 subjects (8 females and 
4 males, age 39 (±12) years, FEV 1 93 (±9) % predicted pre bronchodilation [11] and 
PC 20 1.9 (±1.0) mg/ml). The C O PD  group consisted of 7 subjects (3 females and 4 
males, age 60 (±8) years, FEV 1 54 (±15) %). Asthma and C O PD  were defined 
according to ATS criteria [12].
Patients w ith asthma were included if the PC 20 < 4 m g/m l and the FEV 1 > 80% 
predicted after bronchodilatation. Those w ith C O PD  were included if PC 20 > 4 
mg/ml, the FEV 1 < 80% and the reversibility in FEV 1 after bronchodilators < 10% 
of the predicted value. A cut-off point in PC 20 of 4 m g/m l was chosen to  evaluate 
significant bronchial hyperresponsiveness in asthma. Moreover, C O PD  patients can 
show a mildly reduced value (between 4 and 8 mg/ml) due to the pre-existing 
narrowing of airways w ith lowered FEV 1 w ithout clinical evidence of bronchial 
hyperreactivity [13]. All subjects were in a stable course of the disease for at least 6 
months. Ch
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Exclusion criteria were: other pulm onary disease and a respiratory tract infection in 
the last 8 weeks prior to the study. C O PD  subjects were also excluded if they had a 
previous history of asthma or allergic rhinitis.
The interventions were performed in random  order, each on a separate day, w ith an 
interval of 1 week between intervention days, to eliminate cross-over effects of 
previous interventions. Subjects were asked to refrain from bronchodilating drugs for 
at least 8 hours for short acting drugs and 24 hours for long acting drugs. The 
primary outcom e variables (Raw, sG.w, FEV 1 and PEF) were measured pre and post 
intervention within the same day. The P C 20, measured as secondary variable in 
asthma patients, was determined post intervention, immediately after measuring the 
primary variables on the same day.
The local hospital ethical comm ittee approved the study protocol. A signed and 
dated informed consent was obtained from all subjects. M edication remained 
unchanged during the study.
6.3.2 Interventions
The acid-base shifts were induced by 1) the ingestion of fluid containing am m onium  
chloride (to achieve acidosis), 2) the ingestion of fluid containing sodium 
bicarbonate (alkalosis) or 3) a tablet furosemide 40 mg (loop diuretic alkalosis). 
Placebo consisted of saline. The intervention fluids were calculated and aimed to 
cause a change in base excess (BE) of at least 2 m m ol/l [8;9]. Variables were measured 
at t=90 m in after intervention. The different intervention days were conducted as 
follows:
- Acidosis day: am m onium  chloride (t=0 and 60 min.) + placebo tablet (t=0)
- Alkalosis (bicarbonate) day: bicarbonate (t=0 and 60 min.) + placebo tablet (t=0)
- Alkalosis (furosemide) day: saline (t=0 and t=60 min.) + furosemide (t=0)
- C ontrol day: saline (t=0 and 60 min.) + placebo tablet (t=0)
6.3.3 Measurements
Arterialised capillary blood gas samples were obtained, to determine the induced 
acid-base shifts.
Body plethysmography was used to determine Raw and sG.w [Masterlab Pro, Jaeger 
G m bH , Wuerzburg, Germany]. Raw was calculated as the slope of the pressure- 
volume loop between the first 0.5 l of the in- and expiratory volume and sGaw as the 
inverse ratio of Raw, corrected for the thoracic gas volume. Spirometry was performed 
afterwards, using the same apparatus, to measure FEV 1 and PEF.
In asthma subjects, PC 20 was measured, w ith a maximal dose of histamine of 16 0
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m g/m l [14]. In case of a less than 20% decline at the maximum provocative 
concentration, PC 20 was calculated by extrapolation of the dose-response curves, not 
exceeding twice the maximum dose allowed [15].
Serum calcium, albumin, sodium, potassium and creatinin were determined, because 
abnormalities could potentially influence the results.
6.3.4 Statistics
T he SPSS package, version 9.0 (SPSS Inc., Chicaco, Illinois, USA) was used for 
statistical analysis. Differences were compared by the paired t-test. The primary 
outcom e variables (Raw, sGaw, FEV 1 and PEF) were compared within the same day. 
PC 20 was compared between days. Pearson’s correlation was used to correlate the 
entire range of acid/base shifts (delta BE in acidosis and alkalosis) versus the change 
in the airway calibre (delta R.w, delta sG.w, delta FEV 1 and delta PEF), to determine 
the dose-response relationship between acid-base shifts and alterations in  airway 
calibre. A p-value < 0.05 was considered significant. P-values between 0.05 and 0.20 
are presented as true values, as these may suggest tendencies towards statistical 
significance. Results are expressed as mean (±SD).
6.4 Results
6.4.1 Acidosis day
The intervention caused a decrease in  BE from -0 .4  (±1.3) to -4 .2  (±1.4) mm ol/l in 
all subjects (p<0.01). PaC O 2 did no t change statistically significant (Table 1). The 
pH  decreased from 7.40 (±0.02) to  7.35 (±0.02) (p<0.01). O ther laboratory values 
(serum calcium, albumine, sodium, potassium and creatinin) remained within the 
normal range.
Placebo day Acidosis day Alkalosis day Furosemide day
BE, pre (mmol/l) +0.3 (±1.4) -0.4 (±1.3) +0.5 (±1.3) -0.5 (±1.4)
BE, post (mmol/l) -0.2 (±1.5) -4.2 (±1.4)** +3.8 (±1.5)** +0.5 (±2.0)
p-value NS <0.01 <0.01 NS
PaCÜ2 , pre (kPa) 5.0 (±0.5) 5.0 (±0.5) 5.1 (±0.6) 4.9 (±0.5)
PaCÜ2 , post (kPa) 5.0 (±0.4) 4.8 (±0.4) 5.1 (±0.6) 4.9 (±0.5)
p-value NS NS NS NS
pH, pre 7.41 (±0.03) 7.40 (±0.02) 7.41 (±0.02) 7.40 (±0.02)
pH, post 7.41 (±0.03) 7.35 (±0.02) 7.45 (±0.02) 7.42 (±0.02)
p-value NS <0.01 <0.01 NS
Table 1. Capillary blood gas values pre and post intervention Values are presented as mean (SD). BE: base excess. 
** p < 0.01
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In all subjects, a statistically significant increase was found in  sG™: 0.90 (±0.4) at 
baseline versus 1.00 (±0.4) 1/kPa.s in acidosis (p<0.05). An increase was also found 
in  PEF: 6.90 (±2.2) versus 7.15 (±2.1) (p<0.05). The differences in R™ and FEV 1 
were no t statistically significant (table 2).
Results seemed to be more obvious in asthma than in C O PD  (table 3). This was not 
due to a difference in the power of intervention, because the delta BE was not 
significantly different between the groups (asthma: -3 .4  (±2.7) versus C O PD : -4.6 
(±1.8) (NS)).
In the asthma subjects, PC 20 was no t statistically significant from the placebo day: 2.2 
(±1.1) versus 2.3 (±1.6) m g/m l (NS).
6.4.2 Alkalosis (bicarbonate) day
The base excess (BE) increased from +0,5 (±1.3) to +3.8 (±1.5) mm ol/l in all subjects 
(p<0.01). PaC O 2 did no t change significantly (table 1). The pH  increased from 7.41 
(±0.02) to 7.45 (±0.02) (p<0.01). O ther laboratory values (serum calcium, albumine, 
sodium, potassium and creatinin) remained within the normal range.
In contrast to the findings in acidosis, no statistically significant changes in the 
primary variables were observed (table 2).
PC 20 was no t significantly different from the placebo day: 1.7 (±1.2) versus 2.3 (±1.6) 
m g/m l (NS).
Placebo day Acidosis day Alkalosis day Furosemide day
Raw, pre (kPa.s/l) 0.38 (±0.2) 0.41 (±0.2) 0.39 (±0.2) 0.39 (±0.1)
Raw, post (kPa.s/l) 0.37 (±0.2) 0.37 (±0.2) 0.40 (±0.2) 0.36 (±0.2)
p-value NS NS (0.13) NS NS
sGaw, pre (1/kPa.s) 0.95 (±0.4) 0.90 (±0.4) 0.95 (±0.5) 0.88 (±0.3)
sGaw, post (1/kPa.s) 1.02 (±0.5) 1.00 (±0.4) 0.95 (±0.5) 0.95 (±0.4)
p-value NS (0.19) <0.05 NS NS
FEV1 , pre (l) 2.29 (±0.8) 2.46 (±1.0) 2.47 (±1.1) 2.33 (±0.8)
FEV1 , post (l) 2.43 (±1.0) 2.52 (±1.0) 2.40 (±1.0) 2.42 (±0.9)
p-value NS NS (0.07) NS NS (0.06)
PEF, pre (l/sec) 6.47 (±2.1) 6.90 (±2.2) 6,82 (±1.8) 6.60 (±1.8)
PEF, post (l/sec) 6.81 (±1.8) 7.15 (±2.1) 6.71 (±1.9) 6.63 (±2.0)
p-value NS <0.05 NS NS
Table 2. Variables of airway calibre, pre and post intervention (whole group). Values are presented as mean (SD). Raw: Airflow 
resistance, sGaw: specific airflow conductance, FEV 1 :  forced expiratory volume in 1 sec, PEF: peak expiratory flow.
O
A irw a y  calibre in  p a tien ts  w ith  asthma or C O P D  in  acute m etabolic acid/base shifts.
6.4.3 Placebo day
For the whole group, the sG.w values pre and post intervention were 0.95 (±0.4) and
1.02 (±0.5) 1/kPa.s, bu t the difference did no t reach statistical significance (p=0.19). 
FEV 1 and PEF changed no t statistically significant (table 2).
6.4.4 Furosemide day
Furosemide caused no statistically significant effect on the acid-base equilibrium 
(table 1) or on the primary and secondary outcome variables (table 2).
Asthma (n=12) COPD (n=7)
Raw, pre (kPa.s/l) 0.31 (±0.08) 0.59 (±0.29)
Raw, post (kPa.s/l) 0.29 (±0.08) 0.51 (±0.20)
p-value NS NS
sGaw, pre (1/kPa.s) 1.15 (±0.16) 0.48 (±0.30)
sGaw, post (1/kPa.s) 1.26 (±0.13) 0.54 (±0.38)
p-value <0.05 NS
FEV1 , pre (l) 2.98 (±0.9) 1.56 (±0.4)
FEV1 , post (l) 3.06 (±0.9) 1.60 (±0.4)
p-value NS (0.15) NS
PEF, pre (l/sec) 7.79 (±2.2) 5.36 (±1.3)
PEF, post (l/sec) 8.09 (±1.9) 5.52 (±1.4)
p-value NS (0.10) NS
Table 3. Results in acidosis in asthma versus COPD.Values are presented as mean (SD). Raw: Airflow resistance, 
sGaw: specific airflow conductance, FEV 1 : forced expiratory volume in 1 sec, PEF: peak expiratory flow.
6.4.5 Acidosis and alkalosis
Statistically significant negative correlation’s were found between the delta BE and 
delta FEV 1, delta PEF and delta Raw (table 4). The strongest correlation was found 
between delta BE and delta PEF (r= -0.45, p<0.01) (figure 1). The correlation 
between delta BE and delta sGaw did no t reach statistical significance.
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Figure 1. Delta base excess versus delta peak flow.The filled symbols represent individual asthma patients, the open 
symbols represent individual CO PD  patients. The trend line was calculated for all subjects.
Delta BE versus: r P
Delta sGaw -0.24 0.14 (NS)
Delta FEV1 -0.37 <0.05
Delta PEF -0.45 <0.01
Delta Raw +0.39 <0.05
Table 4. Correlation’s between shifts in BE and changes in Raw, sGaw, FEV 1 and PEF. BE; Base excess; sGaw specific 
airway conductance; FEV 1 : forced expiratory flow in 1 second; PEF: Peak expiratory flow; Raw: airway resistance.
6.5 Discussion
This study evaluates the effect of acute metabolic acid-base shifts on the airway 
calibre of patients w ith asthma or C O PD . In line w ith the hypothesis, acute 
metabolic acidosis caused an increase in  the specific airway conductance and the peak 
expiratory flow. The differences in alkalosis did no t reach statistical significance. 
W hen evaluating the whole range of acid/base shifts in acidosis and alkalosis, 
negative correlation’s were found between the delta BE and the delta FEV 1, delta R,w 
and delta PEF. A single dose of furosemide 40 mg did no t have significant acid/base 
effect. The PC 2 0 , measured in the asthma patients, was no t influenced by the 
acid/base shifts.
A irw a y  calibre in  p a tien ts  w ith  asthma or C O P D  in  acute m etabolic acid/base shifts.
T he induced pH  shifts ranged from 7.35 to 7.45, which reflects approximately 25% 
change in  hydrogen ion concentration. Regarding previous studies, this was 
appropriate for the evaluation of the hypothesised effects; a similar degree of acidosis 
proved to inhibit bronchoconstriction in  dogs [16]. Moreover, in  our previous study 
an almost identical range of acid/base shifts was induced and this was found to 
influence the airway calibre significantly in healthy volunteers [8].
N ot all differences in the outcom e variables of airway calibre reached statistical 
significance. This may be explained as follows. Firstly, the bronchoconstriciton in 
C O PD  is no t really reversible. O ur C O PD  patients were even selected for non- 
reversibilty. Consequently, no large effects could be expected in C O PD  patients. The 
asthma patients were not severely bronchoconstricted, bu t apparently there was still 
room  for improvement. Secondly, a diurnal variability in airway obstruction (with 
most prom inent bronchoconstriction in  the morning) can be observed in patients 
w ith asthma and C O PD  [17-20]. The effects of acidosis, causing relaxation of 
airways, may therefore have been strengthened by the diurnal variability, whereas the 
effects of alkalosis may have been counteracted. This may explain why the results in 
acidosis were statistically significant, while the results in alkalosis were not. 
Tendencies towards significant increases were found in FEV 1 (p=0.06) on the 
furosemide day and in  sGa. (p=0.19) on the placebo day. However, as these 
differences did not reach statistical significance, it is hard to assess the relevance of 
this effect. An additional correction for the diurnal variability could therefore not be 
performed. Thirdly, the study was performed in  a rather small group of patients with 
asthma or C O PD , which may also have contributed to the lack of statistical 
significance in  some of the findings.
Statistically significant correlation’s were found between delta BE and delta FEV 1, 
delta PEF and delta Ra„. Although the correlation’s were only moderate, this could 
suggest the presence of a dose-response relationship between the acid/base shifts and 
alterations in  the airway calibre. M ore severe acid/base disorders may therefore have 
clinically relevant im pact in these patients, especially in  the asthmatics.
N o acute effect of furosemide on the acid/base equilibrium was observed, which is in 
disagreement w ith previous reports [9]. Possible explanations could be that in  this 
study the maximal base excess shift of broadly 2 m m ol/l was found between t=120 
and t=180 m in after consuming furosemide, whereas we measured the shift in base 
excess at t=90 min. However, as the primary variables were measured during the 
consecutive half hour, the effect of our intervention on the airway calibre was 
measured at the maximal acid-base shift. Also a rather variable degree of alkalosis due 
to loop diuretics can be found [9], which might explain why a smaller acid-base shift 
was found. Ch
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An underlying tendency towards bronchial constriction can lead to an increased 
bronchial responsiveness [10]. Therefore, subjects were expected to respond at a 
lower concentration of histamine on  the alkalosis day and at a higher concentration 
on  the acidosis day, as compared to placebo. The differences in alkalosis and acidosis 
were not statistically significant, bu t it needs to be remarked that repeated 
measurement of PC 20 usually show variability of one dose step in  patients with 
asthma [14]. The present differences in PC 20 were less than one dose step. If present, 
the effect was probably too small to detect.
The differences in  the specific airway conductance were more obvious than the 
differences in  the airway resistance. The specific airway conductance is a variable 
corrected for thoracic gas volume, while the inverse airway resistance is not. This 
implies that changes in  specific airway conductance were partly counteracted by 
changes in  the thoracic gas volume. It is possible that changes in  the ventilatory drive 
altered the tonic activity of the respiratory muscle system and the functional residual 
capacity, resulting in  a change in  the thoracic gas volume. This suggests that the 
specific airway conductance is the preferred variable for detecting independent 
changes in  the airway calibre.
The present data are in  agreement w ith our previous study, showing effects of acute 
metabolic acid/base shifts on the airway calibre in healthy volunteers [8]. It is 
interesting to note that in the previous study the findings in alkalosis were statistically 
significant, while in  the current study the findings were significant in  acidosis. This 
difference in findings is possibly due to the characteristics of the studied groups. In 
the healthy volunteers, the results were probably influenced by the fact that 
constriction of airways can more easily be achieved than  a further dilatation of 
airways if the resting tone of sm ooth muscles is normal; a significant effect of 
alkalosis causing constriction, is therefore easier to achieve. In  asthma and C O PD , 
the results were probably influenced by the diurnal variability; the results in  acidosis 
may have been strengthened by an airway relaxation during the day. It appears that 
a physiological phenom enon of acute metabolic acid-base shifts on airways is present, 
bu t as the significance of the findings is easily lost, it seems not of major clinical 
relevance.
Previous studies demonstrate clear effects of C O 2 changes on the airway calibre. 
Primary respiratory acid-base shifts could have greater im pact than metabolic acid- 
base shifts because C O 2 readily passes the cellular membrane, while fixed ions depend 
on pum p mechanisms, which consume tim e and energy. Furthermore, C O 2 can have 
associated effects, such as influencing receptor binding to bronchial agonists and 
mediating the vagal nerve system [16].
A irw a y  calibre in  p a tien ts  w ith  asthma or C O P D  in  acute m etabolic acid/base shifts.
T he study was conducted in  a limited num ber of patients w ith asthma and patients 
w ith C O PD . Nevertheless, a rather consistent and statistically significant pattern of 
effects was found. Regarding the present data, the fluctuations in  the airway calibre 
due to  the acid-base shifts are present bu t in  a rather range, at least when pH  remains 
w ithin the physiological limits.
In  conclusion, acute metabolic acid-base shifts have a moderate effect on the airway 
calibre in patients w ith asthma or C O PD . Metabolic acid-base shifts have no 
apparent effect on the bronchial responsiveness to provocative stimuli, such as 
histamine.
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7.1 Summary
It was hypothesised that non-invasive positive pressure ventilation (NIPPV) could 
resolve peripheral oedema in patients w ith chronic hypercapnic C O PD . Therefore, 
the effect of 24 hours N IPPV  was evaluated on the body fluid homeostasis in 
homogeneous group of chronic hypercapnic C O PD  patients.
15 patients w ith stable chronic hypercapnic C O PD , defined as a persistent 
PaCO2>6.0 kPa [3M:12F, mean age 65 (SD 8) years, FEV 1 35 (15) % predicted] 
received N IPPV  via nasal mask (IPAP/EPAP: 14/4 cm H 2O, FiO 2 0.21). Cardiac 
failure, diuretic dependency and sleep related breathing disorders were excluded. 
Arterial blood gases were obtained at 9.00 (baseline), 10.00, 17.00 and 9.00 o’ clock 
the next day. Primary variables were PaCO 2 (arterial blood gas sampling), body 
weight (digital scale), body water (bioelectrical impedance), leg volume (water- 
displacement volumetry) and plasma levels of aldosterone. Variables were measured 
pre and post NIPPV.
12 subjects completed the study. The m ean (SD) PaC O 2 decreased from 6.77 (0.4) 
at baseline to 6.13 (0.4) at 17.00 (p<0.01) and 6.39 (0.4) kPa at the end of N IPPV  
(both p<0.01, compared to baseline). Subjects w ith the most severe hypercapnia had 
the best response (r=0.66, p<0.05). Aldosteron levels decreased, bu t this was not 
statistically significant (0.64 versus 0.49 nmol/l, p=0 .14). N o significant differences 
were found in  the other variables.
N IPPV  can lower PaCO 2 in  stable chronic hypercapnic C O PD  patients. A 
significant effect on the body fluid homeostasis was no t found in this 24 hours study.
7.2 Introduction
Hypercapnia is associated w ith long term mortality and m orbidity in  patients with 
C O PD  [1-3]. It plays a key role in  the development of peripheral oedema [4]. 
Mechanisms differ from cardiac failure, as right and left ventricular performances and 
cardiac ou tpu t are often normal in  C O PD  patients w ith clinical evidence of oedema 
[5-7]. Responsible factors for fluid retention, associated w ith hypercapnia, are: 1) 
raised levels of catecholamines, 2) activated levels of the renin-angiotensin- 
aldosteron-system (RAAS) and vasopressin, 3) a reduction in renal blood flow and 4) 
retention of water coupled to increased levels of bicarbonate [4;8-10] (figure 1). 
N on invasive positive pressure ventilation (NIPPV) improves the alveolar gas 
exchange [11] and can also enhance cardiac performance [12; 13]. N ot m uch is 
known of the beneficial effect of N IPPV  on horm onal profiles and oedema in 
hypercapnic patients. O ne study in chronic respiratory failure showed a resolution of
2 4  hours N IP P V  a n d  body f lu id  homeostasis in  p a tien ts  with chronic hypercapnic COPD.
oedema and a decrease in body weight w ithin 1 week of NIPPV. The effects could 
probably be attributed to the correction of blood gases by N IPPV  [10]. However, 
patients suffered from a recent hypercapnic and hypoxemic worsening of a chronic 
respiratory failure. Moreover, the respiratory failure was due to various origin. The 
effects of N IPPV  in patients w ith chronic hypercapnic C O P D  have no t been 
evaluated yet. It is no t known if N IPPV  can serve as a tool for resolving oedema. It 
is also no t known w hat the degree and the duration of such an intervention should 
be. Previous studies showed an excretion of bicarbonate w ithin 30 m in after 
decreasing PaC O 2 [14]. This may suggest quick adaptations in the body fluid 
homeostasis after correction of hypercapnia, although the renal adjustm ent of 
bicarbonate is only one of the regulating mechanisms.
As primary goal of the study, we evaluated if N IPPV  during 24 hrs could decrease 
PaC O 2 and consequently cause alterations in the body weight, body water, lower leg 
volume and plasma aldosterone levels in patients w ith stable chronic hypercapnic 
C O PD . Some studies have suggested that the ventilatory benefit of N IPPV  can be 
explained by an underlying relief of respiratory muscle fatigue and /  or an improved 
central ventilatory drive [11;15]. Therefore, we evaluated the chemosensitivity, the 
respiratory muscle function, the hand grip strength and the Borg scores as secondary 
endpoints, to determine whether improvements in ventilatory control could have 
supported the ventilatory effect of NIPPV.
Figure 1. Pathophysiological hypothesis for the formation of oedema in CO PD . ANP: Atrial natriuretic peptide; 
BNP: brain natriuretic peptide; RAAS renin-angiotensin-aldosteron system; SVR: systemic vascular resistance; 
GFR: glomerular filtration rate; ERPF: effective renal plasma flow; Fe,Na: extraction fraction of sodium; + 
stimulaton; -: inhibition. Source: Thorens et al. ERJ 1997; 10: 2553-2559, and MacNee. Am J Resp Crit Care Med 
1994; 150: 833-852.
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7.3 Methods
7.3.1 Subjects
Fifteen patients w ith stable chronic hypercapnic C O PD  (PaCO 2 > 6.0 kPa) 
participated in the study [12 females and 3 males, age 65 (8) years, FEV1 35 (15) %  
predicted [16]]. Ten subjects had clinical evidence of oedema (presence of pitting 
oedema). All women were postmenopausal. C O PD  was established according to 
standards of American Thoracic Society (ATS) [17]. A stability of the disease was 
defined as a fluctuation of FEV1 less than 10% over the last 6 months, and an absence 
of an exacerbation for at least 8 weeks prior to the study.
Subjects w ith a history of cardiac failure or a sleep related breathing disorder were 
excluded. Diuretics, if taken, were w ithdrawn 1 week before entering the study, as 
these could potentially confound the results on the regulation of body water. The 
safety to  withdraw diuretics was determined by an ultrasound evaluation of the heart 
(Power Vision, Toshiba Corporation Medical Systems Company, Tokyo, Japan). 
Subjects were excluded if they were at risk of developing heart failure in  absence of 
diuretics (considered as a left ventricular end diastolic diameter > 58 mm, and/or an 
end systolic diameter > 44 m m  and/or a moderate to severe valvular disease). 
Subjects, who withdrew diuretics, measured their body weight daily at home and 
were instructed to contact the study investigator in case of an increase in  body weight 
of more than 0.5 kg per day or in case of worsening of dyspnea.
The study protocol was approved by the local ethical committee and an informed 
consent was obtained from all subjects.
7.3.2 Study design
All subjects received detailed instructions on how to handle the N IPPV  equipm ent 
in  a training session 1 week prior to the study. A blood gas sample was obtained to 
confirm hypercapnia before entering the study.
For the actual study, subjects were adm itted for 3 days (flow chart, table 1). A quiet 
and separate room  was reserved for performing the study (Medical Centre 
Dekkerswald, Groesbeek, The Netherlands). Primary variables were measured on the 
same tim e of the day, to rule ou t changes due to diurnal variability. M edication 
remained unchanged during the study.
O
2 4  hours N IP P V  a n d  body f lu id  homeostasis in  p a tien ts  with chronic hypercapnic COPD.
Day 1 Day 2 Day 3
12.00 9.00 10.00 17.00 9.00
NIPPV + (start) + + + (end)
Arterial blood gas + + + +
Primary variables + +
Secondary variables + +
Table 1. Flow chart of NIPPV and measurements.
7.3.3 Methods
N IPPV  was administered by bilevel positive airway pressure (BiPAP) (DP90, Taema, 
Antony, France) and applied via nasal mask (Respironics Inc, Murrysville, PA, USA). 
Interm ittent breaks of maximal 30 m in for meals were allowed. The inspiratory 
positive airway pressure (IPAP) and expiratory positive airway pressures (EPAP) were 
set at 14 and 4 cm H 2O respectively, w ith an inspiratory oxygen fraction of 0.21. The 
period 9.00 - 21.00 was considered as daytime treatm ent, the period 21.00 - 9.00 as 
nocturnal treatment.
PaC O 2 was measured by arterial blood gas sampling (Corning Ph127 blood gas 
analyser), obtained at the 9.00 (baseline), 10.00, 17.00 and at 9.00 the next day (flow 
chart, table 1). The level of bicarbonate was determined as actual value, measured 
independently from PaC O 2 .
Primary variables
T he body weight was measured after voiding by a digital scale (FV-150 K, AND 
Instrum ents Ltd., Abingdon, UK).
Bioelectrical impedance was used to  measure the am ount of body water (1500, 
Biostat Ltd., Douglas, Isle of Man, UK) [18], w ith the body composition calculated 
following standardised equations [19].
T he lower leg volume was measured w ith an apparatus based on the water- 
displacement volumetry to estimate effects on the severity of peripheral oedema, as 
it proved an accurate tool for this purpose [20].
Aldosterone was determined as it is the final horm one of the RAAS axis, effective for 
the retention of sodium and water. Plasma atrial natriuretic peptide (ANP) was also 
measured as it represents the counteracting axis, inhibiting RAAS in oedematous 
state. Levels were measured as described earlier [21;22].
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Secondary variables
T he ventilatory response to  hypercapnia (HCVR) was tested, in normoxic 
conditions, by the steady-state m ethod [23;24]. Subjects were connected to a closed 
spirometric circuit, in which the carbon dioxide level could be increased by adjusting 
a 3-way valve, partially short-circuiting a C O 2 absorber in  the inspiratory limb of the 
circuit. The course of carbon dioxide during the procedure was m onitored by end- 
tidal carbon dioxide sampling (M ijnhart Capnolyser, Bilthoven, The Netherlands). A 
capillary blood gas was obtained at the start and after 6 m in of hypercapnic steady 
state to calculate the ventilatory response related to the induced increase in PaC O 2 . 
Measures were performed in a quiet room, in supine position, after relaxation of 15 
minutes. Caffeinated beverages were withheld for 8 hrs.
The apparatus and procedures to measure maximal in- and expiratory m outh 
pressures (Pimax and Pemax) are based on those used by W ilson [25]. The pressure 
inside the tube was measured w ith a pressure transducer (Validyne D P 15-34, 
Northridge, California, USA) and recorded on an ink-writing recorder (Kipp en 
Zonen BD 101, Delft, Netherlands).
H and-grip test dynamom etry was used to test the peripheral muscle strength (Grip-
A, Takei Scientific Instrum ents Inc., Tokio, Japan) [26]. The reproducibility 
(coefficient of variation) of the m ethod is 8.5 % for the non-dom inant hand and
10.1 % for the dom inant hand.
Borg scores were obtained at each visit to assess the sensation of dyspnea [27].
7.3.4 Analysis
The SPSS package (version 6.1, SPSS Inc., Chicaco, Illinois, USA) was used for 
statistical analysis. Differences were compared by paired t-tests or by Wilcoxon 
signed rank tests if no t normally distributed. Differences in body fluid homeostasis 
were evaluated for the whole group and for the subgroup of subjects w ith clinical 
evidence of peripheral oedema separately. A p-value < 0.05 was considered 
statistically significant. Values between 0.05 - 0.20 are presented as true values, as 
these may suggest tendencies towards statistical significance.
Pearson’s correlation was used (or Spearman’s correlation if no t normally distributed) 
for the following correlation analyses: 1) the initial PaC O 2 versus the decrease in 
PaC O 2 (PaCO 2 , baseline -  PaC O 2, 17.00) to determine if the baseline level of PaC O 2 
could predict the ventilatory benefit of NIPPV, 2) the decrease in  PaC O 2 versus the 
differences in the body fluid variables to assess a dose related effect of the blood gas 
correction and 3) the changes in aldosteron versus the changes in  the variables of 
body fluid to determine the causality of the decreases in aldosterone for the 
elimination of body fluid. The results are expressed as mean (SD).
2 4  hours N IP P V  a n d  body f lu id  homeostasis in  p a tien ts  with chronic hypercapnic COPD.
7.4 Results
7.4.1 Subjects
Twelve subjects completed the study. O f the 3 subjects who were withdrawn, 1 had 
an exacerbation and 2 were no t hypercapnic anymore, in spite of repeated previous 
hypercapnic values. Eight of the remaining subjects (67%) had clinical evidence of 
oedema, of w hom 5 (42% of all and 63% of subjects w ith oedema) received diuretics 
until 1 week prior to the study (all furosemide 40 mg daily).
7.4.2 N IPPV
Subjects tolerated the N IPPV  well. The effective overall duration of N IPPV  was 14.1 
(3.8) hours (58 (16) % of time). The daytime duration was 9.5 (1.8) hours (79 (15) 
% of time). The nocturnal duration was significantly shorter compared to the 
daytime duration: 4.6 (3.8) hours (38 (31) % of time) (p<0.05). The applied 
pressures were no t different during day or night.
The PaC O 2 levels decreased significantly at all follow-up measurements, as compared 
to the baseline value of 6.77 (0.4) kPa; Values decreased to 6.24 (0.4) kPa after 1 hour 
and to a lowest value of 6.13 (0.4) kPa at 17.00 (both p<0.01). A partial relapse 
occurred at night, bu t the final PaC O 2 of 6.39 (0.4) was still significantly lower as 
compared to baseline (p<0.01).
The individual PaC O 2 trends are presented in  fig 2 and table 2. Subjects w ith the 
highest baseline PaC O 2 had the best response to NIPPV, noted form a statistically 
significant positive correlation (r=0.69, p<0.05) (figure 2). N IPPV  also improved 
oxygenation; The baseline PaO 2 increased from 7.97 (0.5) kPa to  8.85 (1.4) kPa at 
the end of day 1 and a value of 8.35 (1.4) kPa at the end of treatm ent (p<0.05 and 
p=0.08 respectively). The complete blood gas analyses during N IPPV  are presented 
in table 3.
7.4.3 Primary and secondary outcome variables
Aldosterone levels decreased, bu t this did no t reach statistical significance: 0.64 
versus 0. 49 nmol/l, (p=0.14) (table 2, figure 4A, norm al range: 0.08 -  0.69 nmol/l). 
In  the subjects w ith clinical oedema specifically, differences in aldosterone were in a 
similar range: 0.70 (0.5) versus 0.49 (0.2) nm ol/l (p=0.16). It is interesting to note 
that only 1 subject had a (highly) elevated aldosteron level at baseline (subject 3). It 
can be doubted whether this was a true value or if this was falsely high. No 
statistically significant differences found in  the other fluid variables (table 2, figure
4B-D).
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Figure 2. Individual PaCO 2 during NIPPV The thin lines represent individual values,the thick line the mean values.
Figure 3. Individual baseline PaCO 2 versus decrease in PaCO 2 in response to NIPPV.
2 4  hours N IP P V  a n d  body f lu id  homeostasis in  p a tie n ts  w ith  chronic hypercapnic COPD.
Subject Clinical PaCO2 , Body weight, Body water, Leg volume, Aldosterone,
Oedema Kpa Kg L Ml nmol/l
I 9.00 -  I 17.00 -  II 9.00 pre - post pre - post pre - post pre -  post
1 Yes 6,94 -  5.54 -  6.94 91.7 -  91.1 39 -  39 2799 -  2756 0,28 -  0.31
2 Yes 7,45 -  7.21 -  6.81 91.3 -  91.2 43 -  45 2841 -  2794 0,63 -  0.28
3 Yes 7,37 -  5.75 -  6.65 75.0 -  75.9 35 -  35 2438 -  2434 1,70 -  0.68
4 Yes 6,53 -  6.48 -  6.27 82.0 -  81.6 32 -  33 2563 -  2616 0,84 -  0.67
5 Yes 6,14 -  6.06 -  6.07 89.4 -  89.6 40 -  38 2434 -  2401 0,56 -  0.43
6 Yes 6,58 -  6.15 -  6.43 69.5 -  68.9 32 -  32 2460 -  2521 0,30 -  0.45
7 Yes 7,31 -  6.18 -  6.85 87.0 -  85.5 41 -  40 2431 -  2252 0,66 -  0.43
8 Yes 6,28 -  5.99 -  5.55 66.0 -  66.4 37 -  37 2809 -  2919 0,61 -  0.68
9 No 6,85 -  5.81 -  6.13 65.6 -  64.4 34 -  32 2210 -  2253 0,44 -  0.67
10 No 7,05 -  6.22 -  6.71 59.3 -  59.5 29 -  29 1644 -  1711 0,59 -  0.45
11 No 6,22 -  6.05 -  6.22 67.8 -  67.8 44 -  43 2875 -  2874 0,68 -  0.56
12 No 6,52 -  6.07 -  6.09 58.2 -  57.4 36 -  35 2147 -  2083 0,33 -  0.26
Mean, 1-8 6.83 -  6.17 -  6.45 81.5 -  81.3 37.3 -  37.2 2597 -  2587 0.70 -  0.49
SD, 1-8 0.5 -  0.5 -  0.5 10 -  10 4 - 4 187 - 226 0.5 -  0.2
p-value <0.05 - <0.01 NS NS NS 0.16
Mean, all 6.77 -  6.13 -  6.39 75.2 -  74.9 37 - 36 2471 -  2468 0.64 - 0.49
SD, all 0.4 - 0.4 - 0.4 12 -  12 5 - 5 356 -  357 0.4 - 0.2
p-value <0.01 - <0.01 NS NS NS 0.14
Table2. Individual differences in fluid homeostasis related to decrease in PaCO 2 . Measurements of PaCO 2 : I 9 0 0 : day 1 at 9.00, I 1 7 0 0 : 
day 1 at 17.00 and II 9 0 0 : day 2 at 9.00. The normal range of plasma aldosteron is 0.08 -  0.69 nmol/l. Statistics: Values in italics 
(subjects 1-8) represent analysis of subjects with clinical oedema specifically. All follow-up measurements were compared to baseline.
I 9.00 (baseline) I 10.00 I 17.00 II 9.00 (end)
pH 7.366 (0.03) 7.389 (0.03)** 7.394 (0.03)* 7.384 (0.03)*
PaCO2 , kPa 6.77 (0.5) 6.24 (0.4)** 6.13 (0.4)** 6.39 (0.4)**
Base excess, mmol/l 2.6 (1.6) 2.6 (1.9) 2.4 (2.3) 2.7 (2.0)
Actual bicarbonate, mmol/l 27.6 (2.1) 27.2 (2.4) 27.1 (2.1) 27.4 (2.4)
PaO2 , kPa 7.97 (1.2) 8.03 (0.9) 8.85 (1.4)* 8.35 (1.4)
SaO2, % 88.7 (5) 90.3 (3) 90.9 (4)* 90.1 (4)
Table 3. Blood gas analyses during NIPPV.Results are presented as mean (SD). I 9 0 0 : day 1 at 9.00; I 1 0 0 0 : day 1 at 10.00; I 1 7 0 0 : day 
1 at 17.00; II 9 0 0 : day 2 at 9.00. Statistics (follow-up measurements compared to  baseline): * p<0.05, **p<0.01
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Figure 4  A-D. Body fluid homeostasis, pre and post NIPPV.The th in  lines represent individual values. 
The thick lines the mean of the group.
A moderate positive correlation was found between the change in PaC O 2 and the 
change in aldosterone, bu t this was no t statistically significant (r=0.43, p=0.16). The 
correlation’s between the PaC O 2 and the other variables of body fluid were not 
statistically significant.
N o statistically significant correlation existed between the changes in aldosteron and 
the changes in body water, body weight or leg volume. However, deleting the results 
of subject 3 (because of the outlying aldosteron level, figure 4A) resulted in a stronger 
correlation between the change in aldosteron and the change in the leg volume; the 
correlation changed from poor, including subject 3, (r=0.28, p=0.38) to moderate
(r=0.53, p=0.096).
ANP levels could only be determined satisfactorily in 7  subjects, because of 
insufficient material in  the other subjects. The mean (SD) value was 25.0 (11) pmol/l 
at baseline and 22.3 (7) pm ol/l at the end of treatm ent, which was no t statistically 
significant (normal range: 3-23).
0 0
2 4  hours N IP P V  a n d  body f lu id  homeostasis in  p a tien ts  with chronic hypercapnic COPD.
T he secondary variables of H CV R , Pimax, Pemax and Borg scores improved, but 
none of the differences reached statistical significance (table 4).
Pre Post P-value
HCVR min-1.kPa-1 4.4 (3.5) 6.4 (4.6) 0.16
P,max, kPa 4.9 (1.2) 5.4 (1.7) 0.066
Pemax, kPa 7.0 (1.8) 8.2 (1.6) 0.11
P „ , Kg 24 (7) 25 (7) NS
Borg 3.2 (2.5) 1.8 (1.8) 0.090
Table 4 . Secondary variables. HCVR: ventilatory response to hypercapnia, Pemax: maximal expiratory m outh pressure, Pimax: 
maximal inspiratory m outh pressure, Pgrip: maximal hand grip strength.
7.5 Discussion
As an explorative study, we evaluated the effect of 24 hours N IPPV  on PaC O 2 and 
the effect on the body fluid homeostasis in a homogeneous group of C O P D  patients 
w ith stable chronic hypercapnia. N IPPV  lowered PaC O 2 by broadly 0.5 kPa, from 
6.8 kPa to 6.1 kPa. Subjects w ith the most severe hypercapnia had the best PaC O 2 
response. An effect on the body fluid homeostasis was only noted form a decrease in 
the plasma aldosterone levels, bu t the difference was no t statistically significant. 
N IPPV  was effectively used for more than 60 %  of the total time and for almost 80%  
of the day. It is uncertain whether this high effectiveness can be attributed to the 
training session prior to study, bu t it is clear that the subjects felt comfortable with 
the intervention. The ability of N IPPV  to decrease PaC O 2 was obvious. A positive 
correlation existed between the baseline PaC O 2 and the decrease in PaC O 2 , implying 
that N IPPV  was especially beneficial in patients w ith severe hypercapnia.
To our knowledge, no studies have evaluated the effects of NIPPV  on body fluid and 
oedema in patients w ith stable chronic hypercapnic C O PD . The current study was 
therefore performed as an explorative study. It is likely that changes in  horm one levels 
are the first and m ost sensitive sign to  detect, as these are believed to occur in advance 
to the changes in the body water. A non-statistically significant decrease was found 
in the aldosterone levels, bu t a moderate correlation existed between the changes in 
aldosterone and the leg volume. The latter suggests a causal relationship between 
aldosterone and oedema. It appears that, in  agreement w ith the hypothesis, slight 
alterations in the body fluid homeostasis occurred in some of the subjects. However, 
the intervention was insufficient to cause significant overall changes in the group.
It should be noted that the baseline aldosterone levels were already normal. The latter
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is in contrast to the studies describing elevated levels in oedematous C O P D  [8]. 
There may be 2 reasons for this finding. Firstly, increased levels of RAAS hormones 
are often due to the use of diuretics [4] and secondly, elevated levels of natriuretic 
peptides may have inhibited RAAS [30]. N one of our subjects received diuretics 
during the study and indeed ANP levels were increased at baseline (mean 25 pmol/l, 
versus a normal range of 3-23 pmol/l).
The effects of decreasing PaC O 2 on body fluid hypothesised could be expected to be 
m ost pronounced in subjects w ith clinical evidence of oedema. The latter in  fact was 
the case in the majority of the subjects. The results of the subgroup of subjects with 
clinical oedema were in a similar range as those in the whole group. It needs to be 
remarked that the remaining subjects may no t have differed much. There may have 
been a certain degree of water retention in these subjects, although this was no t 
clinically present. Especially, when it is remarked that marginal oedema is hard to 
detect in general practice.
The present study is no t easily comparable w ith the study of Thorens et al., who did 
show resolution of oedema by N IPPV  [10]. Their study evaluated N IPPV  for a week, 
whereas we evaluated a duration of 24 hours. Moreover, their patients had various 
underlying diseases and recovered from a worsening of chronic respiratory failure. An 
improvement of the general condition may also have contributed. The decrease in 
PaC O 2 of 3 kPa in de study of Thorens et al. was larger than in our study (0.5 -  1 
kPa). As the mean baseline PaC O 2 was 6.8 kPa (range 6.1 -  7.5 kPa) a decrease of
0.5 - 1 kPa was enough to reach normal PaC O 2 limits. Oxygenation also improved, 
which is im portant as hypoxemia also contributes to the retention of water [28;29]. 
The absence of significant changes in the body water may be attributed to an 
insufficient duration. However the rather small decrease in PaC O 2 may also have 
played a role, even though PaC O 2 values became near norm al limits. Regarding the 
previous and the present results, N IPPV  may prove to cause significant resolution of 
oedema after a duration in  between a day and a week. It is likely that it will only be 
detectable if applied in patients w ith severe chronic hypercapnic C O PD  and with 
clinical signs of oedema. However, such a trial in a homogeneous group of stable 
C O PD  patients may no t easily be performed.
M any studies evaluated the relationship between mechanical positive pressure 
ventilation and haemodynamic alterations [31]. However, the majority of these 
studies investigated mechanical cardiopulmonary interactions and tried to explain 
how positive pressure ventilation can interfere w ith right or left ventricular function. 
Some studies also found haem odynam ic effects of non-invasive mechanical 
ventilation [12;13], bu t others found no significant effects [32]. O ne study showed
2 4  hours N IP P V  a n d  body f lu id  homeostasis in  p a tien ts  with chronic hypercapnic COPD.
no haemodynamic effects up to 20 cm H 2 0  inspiratory pressure, except when positive 
end expiratory pressure (PEEP) (5-10 cmH20) was added [33]. It is unlikely that such 
effects were of major relevance in our study, as the administered pressures were 
significantly lower.
N IPPV  caused a tendency towards improved Borg scores. Although the results may 
have been biased because an open study was conducted, this may suggest a positive 
effect of N IPPV  on the sensation of dyspnea. In agreement w ith earlier studies [34], 
N IPPV  appeared to improve the respiratory muscle function. However, the 
differences were no t statistically significant. Positive effects of N IPPV  on the 
respiratory muscles may be due to muscle unloading or to  increased contractile 
properties. The latter could directly be related to  lowering PaC O 2 [35]. Increased 
contractile properties were no t measured from an improved hand grip strength, but 
the m ethod to measure this have been too insensitive to detect small effects. An 
increase in ventilatory response to hypercapnia was found. Again this was not 
statistically significant, possibly due the rather small num ber of subjects. The 
findings could support the hypothesis that improvements by N IPPV  can be 
explained by an underlying relief of muscle fatigue and /  or improvements in central 
ventilatory drive [11;15].
H ypercapnia is associated w ith  poor prognosis C O P D . T he correction of 
hypercapnia can therefore be a goal for treatm ent. Regarding the rather simple 
procedure, N IPPV  may be considered in  the management of chronic hypercapnic 
patients. Especially those w ith severe hypercapnia seem to benefit. Small devices are 
now easy to handle and have become available for various conditions, including the 
home situation. It is im portant to recognise the hypercapnia associated morbidity, as 
this can seriously affect the patients quality of life. The present study evaluates the 
effect of N IPPV  on the resolution of oedema. It seems that a 24 hours intervention, 
lowering PaC O 2 by broadly 0.5 kPa, is insufficient for the elimination of oedema.
In conclusion, N IPPV  is effective in  lowering PaC O 2 . W hen applied for the 
resolution of oedema in patients w ith stable chronic hypercapnic C O PD , the 
duration of 24 hours appears too short to have significant effect.
Ch
ap
te
r 
7
Lo
op
 
di
ur
et
ic
s 
an
d 
hy
pe
rc
ap
ni
a 
in 
ch
ro
ni
c 
ob
str
uc
tiv
e 
pu
lm
on
ar
y 
di
se
as
e.
C hapter 7
7.6 References
1. Cooper CB: Life expectancy in  severe COPD. Chest 1994; 105: 335-337.
2. Costello R, Deegan P, Fitzpatrick M , McNicholas WT: Reversible hypercapnia in  chronic 
obstructive pulmonary disease: a distinct pattern o f respiratory failure with a favorable 
prognosis. Am.J.Med. 1997; 102: 239-244.
3. Foucher P  Baudouin N , M erati M , et al: Relative survival analysis o f252patients with 
COPD receiving long- term oxygen therapy. Chest 1998; 113:1580-1587.
4. Anand IS, Chandrashekhar Y, Ferrari R, et al: Pathogenesis o f congestive state in  chronic 
obstructive pulmonary disease. Studies o f body water and sodium, renal function, 
hemodynamics, and plasma hormones during edema and after recovery. Circulation 
1992; 86:12-21.
5. Jezek V, Schrijen F: Left ventricular function in  chronic obstructive pulmonary disease 
with and without cardiac failure. Clin.Sci.Mol.Med. 1973; 45: 267-279.
6. Khaja F, Parker JO: Right and left ventricular performance in  chronic obstructive lung 
disease. Am.Heart J. 1971; 82: 319-327.
7. MacNee W: Right ventricular function in  cor pulmonale. Cardiology 1988; 75 Suppl 
1:30-40: 30-40.
8. MacNee W: Pathophysiology o f cor pulmonale in  chronic obstructive pulmonary disease. 
Part two. Am.J.Respir.Crit.Care Med. 1994; 150:1158-1168.
9. MacNee W: Pathophysiology o f cor pulmonale in  chronic obstructive pulmonary disease. 
Part One. Am.J.Respir.Crit.CareMed. 1994; 150: 833-852.
10. Thorens JB, R itz M , Reynard C, et al: Haemodynamic and endocrinological effects o f 
noninvasive mechanical ventilation in  respiratory failure. Eur.Respir.J. 1997; 10:2553­
2559.
11. H ill NS: Noninvasive ventilation. Does it  work, for whom, and how? Am.Rev.Respir.Dis. 
1993; 147:1050-1055.
12. Marangoni S, Vitacca M, Quadri A, Schena M , Clini E: Non-invasive haemodynamic 
effects o f two nasal positive pressure ventilation modalities in  stable chronic obstructive 
lung disease patients. Respiration 1997; 64:138-144.
13. Scharf SM: Effects o f continuous positive airway pressure on cardiac output in  
experimental heart failure. Sleep. 1996; 19: S240-S24.
14. Gledhill N , Beirne GJ, Dempsey JA: Renal response to short-term hypocapnia in  man. 
Kidney Int. 1975; 8: 376-384.
15. E lliott MW, M ulvey DA, Moxham J, Green M , Branthwaite M A: Domiciliary 
nocturnal nasal interm ittent positive pressure ventilation in  COPD: mechanisms 
underlying changes in  arterial blood gas tensions. Eur.Respir.J. 1991; 4:1044-1052.
2 4  hours N IP P V  a n d  body f lu id  homeostasis in  p a tien ts  with chronic hypercapnic COPD.
16. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC: Lung 
volumes and forced ventilatory Bows. Rev.Mal.Respir. 1994; 11 Suppl 3: 5-40.
17. Standards for the diagnosis and care o f patients with chronic obstructive pulmonary 
disease. American Thoracic Society. Am.J.Respir.Crit.Care Med. 1995; 152: S77-121.
18. Segal KR, Van Loan M, Fitzgerald PI, Hodgdon JA, Van Itallie TB: Lean body mass 
estimation by bioelectrical impedance analysis: a four-site cross-validation study. 
Am.J.Clin.Nutr. 1988; 47: 7-14.
19. Kushner RF, Schoeller DA: Estimation o f total body water by bioelectrical impedance 
analysis. Am.J.Clin.Nutr. 1986; 44: 417-424.
20. Brijker F, Heijdra YF, Van Den Elshout FJ, Bosch FH, Folgering H T: Volumetric 
measurements o f peripheral oedema in  clinical conditions. 
Clin.Physiol.2000.Jan.;20.(1.):56.-61. 20: 56-61.
21. De M an AJ, Hofman JA, Hendriks T, Rosmalen FM, Ross HA, Benraad TJ: A direct 
radio-immunoassay for aldosterone: significance o f endogenous cortisol. Neth.J.Med. 
1980; 23: 79-83.
22. Rosmalen FM, Tan AC, Tan HS, Benraad TJ: A sensitive radioimmunoassay o f atrial 
natriuretic peptide in  human plasma, using a tracer with an immobilized glycouril agent. 
Clin.Chim.Acta 1987; 165: 331-340.
23. Folgering HT, Bernards JA, Biesta JH, Smolders F: Mathematical analysis o f the response 
o f lung ventilation to CO2 in normoxia and hyperoxia. Pflugers Arch. 1974; 347: 347­
350.
24. Smolders FD, Folgering HT, Bernards JA: Capnostat and oxystat. Electronic devices to 
automatically maintain the end-tidal PCO2 and PO 2 o f a subject connected to a closed 
respiratory circuit a t adjustable levels. Pflugers Arch. 1977; 372: 289-290.
25. Wilson SH, Cooke NT, Edwards RH, Spiro SG: Predicted normal values for m axim al 
respiratory pressures in  caucasian adults and children. Thorax 1984; 39: 535-538.
26. Spijkerman DC, Snijders CJ, Stijnen T, Lankhorst GJ: Standardization o f grip strength 
measurements. Effects on repeatability and peak force. Scand.J.Rehabil.Med. 1991; 23: 
203-206.
27. Borg G: Ratings o f perceived exertion and heart rates during short-term cycle exercise and 
their use in  a new cycling strength test. Int.J.Sports Med. 1982; 3:153-158.
28. Anderson RJ, Pluss RG, Berns AS, et al: Mechanism o f effect o f hypoxia on renal water 
excretion. J.Clin.Invest. 1978; 62: 769-777.
29. Reihman DH, Farber M O, Weinberger M H, et al: Effect o f hypoxemia on sodium and 
water excretion in  chronic obstructive lung disease. Am.J.Med. 1985; 78: 87-94.
30. Anderson JV, Struthers AD, Payne N N , Slater JD, Bloom SR: Atrial natriuretic peptide 
inhibits the aldosterone response to angiotensin I I  in  man. Clin.Sci. 1986; 70: 507-512.
Ch
ap
te
r 
7
Lo
op
 
di
ur
et
ic
s 
an
d 
hy
pe
rc
ap
ni
a 
in 
ch
ro
ni
c 
ob
str
uc
tiv
e 
pu
lm
on
ar
y 
di
se
as
e.
C hapter 7
31. H urford WE: Cardiopulmonary interactions during mechanical ventilation. 
Int.Anesthesiol.Clin. 1999; 37: 35-46.
32. Confalonieri M, Gazzaniga P, Gandola L, et al: Haemodynamic response during 
initiation o f non-invasive positive pressure ventilation in  COPD patients with acute 
ventilatory failure. Respir.Med. 1998; 92: 331-337.
33. Ambrosino N , Nava S, Torbicki A, et al: Haemodynamic effects o f pressure support and 
PEEP ventilation by nasal route in  patients with stable chronic obstructive pulmonary 
disease. Thorax 1993; 48: 523-528.
34. Petrof BJ, K im off RJ, Levy RD, Cosio MG, Gottfried SB: Nasal continuous positive 
airway pressure facilitates respiratory muscle function during sleep in  severe chronic 
obstructive pulmonary disease. Am.Rev.Respir.Dis. 1991; 143: 928-935.
35. Juan G, Calverley P, Talamo C, Schnader J, Roussos C: Effect o f carbon dioxide on 
diaphragmatic function in  human beings. N.Engl.J.Med. 1984; 310: 874-879.
C hapter 8
Summary and conclusions
1Q7
Lo
op
 
di
ur
et
ic
s 
an
d 
hy
pe
rc
ap
ni
a 
in 
ch
ro
ni
c 
ob
str
uc
tiv
e 
pu
lm
on
ar
y 
di
se
as
e.
C hapter 8
8.1 Introduction
Chronic obstructive pulm onary disease (COPD) represents the diseases chronic 
bronchitis, emphysema and peripheral airway obstruction, and is characterised by an 
expiratory flow limitation. It is one of the 5 most frequent causes of death in 
industrialised countries. C O P D  is usually a progressive disease. Patients can develop 
hypoxaemia and hypercapnia during the course of the disease. The latter can be 
associated by episodes of peripheral oedema. There is an urge for accurate monitoring 
and treatm ent of chronic hypercapnic C O PD  patients w ith signs of oedema, as the 
prognosis is generally poor. W ithout treatment, 2 out of 3 patients die within 5 years. 
Loop diuretics are frequently prescribed because of their potent water excreting 
capacity. However, the use of loop diuretics is often complicated by a metabolic 
alkalosis, which may have serious implications in C O PD  patients w ith hypoxemia 
and hypercapnia.
A. A metabolic alkalosis causes a diminished chemoreceptor stimulation. This 
results in a decreased alveolar ventilation and an increased arterial carbon dioxide 
tension in order to stabilise the acid-base equilibrium. This may worsen the pre­
existing hypoxemia and hypercapnia.
B. Alkalosis may increase the contractility of bronchial sm ooth muscles, possibly 
causing a further bronchial constriction. The pre-existing ventilation-perfusion 
mism atch may progress and the gas-exchange may be further endangered.
Since hypoxaemia and hypercapnia contribute to the development of oedema, it is 
likely that a worsening in oxygen and carbon dioxide tensions will lead to a increased 
diuretic dependency. The suggested mechanisms may m aintain or become more 
serious. Patients may experience a further deterioration of an already poor clinical 
condition.
8.2 Chapter 2
W hen evaluating the nocturnal hypoxemia in C O PD , the m onitoring equipm ent or 
an unfamiliar hospital environment can cause sleep disturbances w ith frequent 
arousals and wakefulness. Since it may have consequences for the observed severity 
of nocturnal hypoxaemia, it was investigated if fewer desaturations could be observed 
during a m onitoring night. Fourteen stable C O PD  patients were subjected to 3 
different m onitoring nights: oximetry at home, polysomnography at home and 
polysomnography in  the hospital.
Sum m ary an d  conclusions
T he m edian nocturnal SaO 2  was lower during oxim etry than  during 
polysomnography at home: 88.5%  (range 80-92) versus 89.7%  (77-93) (p<0.05). 
T he fraction of time in hypoxia (SaO2<90%) was also higher during oximetry than 
during polysomnography at home: 59.9%  (6-100) versus 40.8%  (5-100) (p<0.01). 
T he time in desaturation reduced by more than half when adding polysomnographic 
equipm ent in the home situation: 50.4% (4-91) during oximetry versus 22.1% 
(3-63) during polysomnography (p<0.01). Comparison of sleep architecture during 
PSG nights showed a higher arousal index in the hospital than at home: 5.6 /  hr 
(2-16) versus 2.5 /  hr (1-6) (p<0.05), and less REM sleep as a fraction of total sleep:
11.5% (7-27) in hospital versus 17.6% (5-24) at home (p<0.05). N o differences in 
nocturnal SaO 2  were found.
It was concluded that the artefacts due to  sleep m onitoring equipment may cause an 
underestim ation of the degree of nocturnal hypoxaemia in C O PD  patients. The 
addition of an unfamiliar environment causes more sleep disruption, bu t this does not 
further affect nocturnal SaO 2 .
8.3 Chapter 3
W ater-displacement volumetry can be used to quantify peripheral oedema from the 
volume of the leg, bu t the application in patients w ith peripheral oedema of cardiac 
or pulm onary origin has no t been described. The suitability for this purpose was 
evaluated by using a water-displacement apparatus, designed in  our own laboratory. 
T he volumetric results were compared to the ankle circumference and the body 
weight.
T he reproducibility of the apparatus w ith a solid object and in 10 non-oedematous 
clinical patients showed a coefficient of variation of 0.16%  and of 0.47%  respectively. 
T he diurnal variability, assessed in 10 other patients w ith persisting peripheral 
oedema was 5.9% (p<0.001) as compared to 2.4%  (p<0.01) for the ankle 
circumference and no significant change in body weight. The effect of treatm ent on 
the severity of peripheral oedema was evaluated in another 9 patients w ith peripheral 
oedema, w ho were in  need of diuretic treatm ent. The leg volume, ankle 
circumference and the body weight decreased significantly after treatment: 13.1% 
(p<0.01), 7.1%  (p<0.05), and 5.9% (p<0.05) respectively.
It was concluded that: 1) Water-displacement volumetry is highly reproducible,
2) A diurnal variability of peripheral oedema can be found, and, most im portant,
3) Volumetry is a suitable and sensitive tool for m onitoring peripheral oedema.
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8.4 Chapter 4
Furosemide-induced alkalosis can cause a decrease in alveolar ventilation. It was 
evaluated if the discontinuation of furosemide would decrease PaCO 2 and increase 
daytime and nocturnal oxygenation. Furosemide, previously prescribed for the 
treatm ent of peripheral oedema, was discontinued for 1 week in 20 patients with 
stable C O PD  in a randomised, double-blind, placebo-controlled, cross-over trial. 
Correction of the alkalosis resulted in a significant increase in ventilation: 10.4 (6.7­
15.4) l/m in at baseline versus 11.6 (8.7-14.0) l/m in after discontinuation of 
furosemide (p<0.05). The median arterial carbon dioxide tensions decreased by 0.5 
kPa from 6.0 (4.6-8.5) kPa at baseline to 5.5 (4.3-8.1) kPa after discontinuation of 
furosemide (p<0.01). Daytime and nocturnal oxygenation did no t improve. It was 
concluded that discontinuation of furosemide, prescribed for the treatm ent of 
peripheral oedema, decreases arterial carbon dioxide tensions in  patients w ith severe
C O PD .
8.5 Chapter 5
Metabolic acid-base shifts may influence the contractility of bronchial smooth 
muscles and consequently alter the hum an airway calibre. This chapter describes the 
effects of acute metabolic acid-base shifts on airway resistance and specific airway 
conductance in 15 healthy volunteers in a double blind, placebo controlled study. 
The bronchial responsiveness to histamine, the respiratory muscle strength and the 
peripheral hand grip strength were measured, as secondary endpoints. Alkalosis was 
induced by the ingestion of a calculated am ount of bicarbonate, acidosis by 
am m onium  chloride, aimed at a change in the base excess of 2 m m ol/l in both 
directions. Oral saline was used as placebo.
The base excess increased from -0 ,3  (-3.0-1.9) to 3.0 (1.0-4.8) mm ol/l in alkalosis 
and decreased from -0.2 (-2.0-2.2) to -3 .5  (-6.3-1.1) mm ol/l in acidosis (both 
p<0.01), suggesting adequate interventions. Airway resistance increased slightly in 
alkalosis: 0.156 (0.134-0.263) kPa.s/l at baseline to  0.169 (0.132-0.271) kPa.s/l after 
induction of alkalosis (p<0.05). The conductance did no t decrease statistically 
significant. The changes in acidosis were contrary to those found in alkalosis, but 
these did no t reach statistical significance. The marginal effects suggest that a 
physiological influence of acid-base shifts on airway calibre is present, bu t that it has 
no major clinical im pact in healthy subjects. N o effects of the interventions were 
found on the bronchial responsiveness to histamine, the respiratory muscle strength 
and the peripheral grip strength.
S u m m a ry  a n d  conclusions
It was concluded that the mild effects of acute metabolic acid-base shifts on airway 
calibre are present in healthy volunteers.
8.6 Chapter 6
T he effects of metabolic acid-base shifts on airway calibre was consequently evaluated 
in patients w ith asthma or C O PD . The same interventions were used, as described 
in chapter 5. In addition, an acute metabolic alkalosis was induced by furosemide. 
T he latter was added to assess the clinical relevance of this type of alkalosis on the 
airway calibre.
N ineteen subjects participated in a double blind, placebo controlled trial. The group 
consisted of 12 asthma patients (8 F, mean age 39 (±SD 12) years, FEV 1 93 (±9) % 
predicted, PC 20 histamine 1.9 (±1.0) mg/ml) and 7 C O PD  patients (3 F, age 60 (±8) 
years, FEV 1 54 (±15) % predicted). Changes in airway resistance (R,w), specific 
airway conductance (sG.w), FEV 1 and PEF were measured as primary variables. PC 20 
histamine was measured as secondary variable in asthma.
In acidosis, BE decreased from -0.4 (±1.3) to -4.2 (±1.4) m m ol/l (p<0.01). sG.w and 
PEF increased (all subjects): 0.90 (±0.4) vs. 1.00 (±0.4) 1/kPa.s and 6.90 (±2.2) vs. 
7.15 (±2.1) l/sec respectively (both p<0.05). In  alkalosis (bicarbonate), BE increased 
from +0.5 (±1.3) to +3.8 (±1.5) mm ol/l (p<0.01), bu t no statistically significant 
changes in primary variables were observed. W hen evaluating the entire range of 
acid-base shifts, statistically significant correlation’s were found between the delta BE 
and respectively delta FEV 1 (r=-0.37, p<0.05), delta R,w (r= +0.39, p<0.05) and delta 
PEF (r=-0.45, p<0.01). PC 20 histamine did no t change.
It was concluded that acute metabolic acid-base shifts have a moderate effect on the 
airway calibre of patients w ith asthma or C O PD .
8.7 Chapter 7
Hypercapnia plays a major role in  the development of peripheral oedema in C O PD . 
T he effect of decrease in arterial carbon dioxide tensions, by non-invasive ventilation, 
on the elimination of body water was evaluated in this chapter. Fifteen stable chronic 
hypercapnic C O PD  patients received 'bilevel positive airway pressure’ (BiPAP), via 
nasal mask as m uch as tolerable by the individual patients, during 24 hours. All 
subjects tolerated the treatm ent well. PaC O 2 decreased from 6.77 (0.4) kPa at 
baseline to 6.13 (0.4) kPa at 17.00 (p<0.01) and 6.39 (0.4) kPa at the end of 
treatm ent (both p<0.01, compared to baseline). Subjects w ith the m ost severe 
hypercapnia had the best response (r=0.66, p<0.05). The aldosteron levels decreased, Ch
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but this was no t statistically significant (0.64 versus 0.49 nmol/l, p=0.14). No 
significant differences were found in the other variables.
The conclusion was that non-invasive ventilation can serve as a tool for treating 
chronic hypercapnia in C O PD , bu t a 24 hour intervention seems no t sufficient for 
the resolution of oedema.
8.8 Clinical relevance and recommendations
The use of furosemide was associated by a decreased alveolar ventilation and hereby 
an increase in the arterial carbon dioxide levels in patients w ith C O PD . This was in 
agreement w ith the hypothesis (figure 1, phenom enon A). A rise in carbon dioxide 
tensions can have consequences for long term m orbidity and mortality. The findings 
are therefore of clinical importance, in particular in C O PD  patients w ith a tendency 
towards retention of carbon dioxide. The physician should be aware of the 
ventilatory depressant effect, before prescribing loop diuretics to a patient with 
C O PD . The discontinuation of furosemide did no t to improve the oxygenation, 
which was in discrepancy w ith the advantageous effect of the increased alveolar 
ventilation. It is likely that counteracting mechanisms were present, such as 1) a 
worsened diffusion capacity for oxygen, due to an increased interstitial fluid retention 
in  the lung, or 2) an increased ventilation /  perfusion mismatch, due to thickening 
of the bronchial walls, decreased clearance of sputum  or lowered functional residual 
capacity (figure 1, phenom enon C and D  respectively). Furosemide has a negative 
effect of on the alveolar ventilation, bu t apparently positive additional effects, on the 
gas exchange. This suggests that C O PD  patients may benefit from other types of 
diuretics, w ithout a complicating alkalosis.
An effect of metabolic acid-base changes on the hum an airway calibre was also found. 
The changes were statistically significant bu t rather small, suggesting that the effect 
(figure 1, phenom enon B) is only of m inor clinical relevance in  healthy humans. In 
patients w ith asthma or C O PD , it seems that acute metabolic acid-base shifts only 
have a moderate effect on the airway calibre.
Mechanical ventilation can be needed in C O PD  patients when standard treatm ent 
fails to rem ain gas exchange w ithin acceptable limits. Although apparently 
insufficient for resolving oedema (figure 1, phenom enon E), 24 hours non-invasive 
ventilation proved to be well accepted and to be efficient for the treatm ent of 
hypercapnia. W ith  respect to the findings in  the literature about life expectancy of 
hypercapnic C O P D  patients, and considering the simple procedure of ventilatory 
support, the therapy may be considered in chronic hypercapnic C O PD  patients.
Sum m ary an d  conclusions
8.9 General conclusion
Clinically relevant interactions between fluid homeostasis, acid-base regulation and 
ventilatory control in patients w ith C O PD  appear to be present. Awareness of these 
interactions may provide clues to prevent deterioration of the patients clinical 
condition. The use of loop diuretics in  severe C O PD  needs to be reconsidered, 
because of the significant ventilatory depressing effect. Moreover, the alkalosis due to 
loop diuretics may further endanger the alveolar gas exchange by affecting the 
bronchial contractility. However, the latter appeared only of m inor clinical relevance. 
O ther types of diuretics seem beneficial, bu t further research is needed to establish 
the optimal diuretic strategy in  patients w ith severe C O PD  and oedema.
Figure 1. Revised model on body fluid, acid-base regulation and ventlatory control in CO PD .
A: Present in C O PD  (chapter 4)
B: Physiological phenom enon (chapter 5), but only of minor clinically relevance in CO PD  (chapter 6) 
C: Suggested effect (chapter 4)
D: Suggested effect (chapter 5)
E: N ot present, when observed for 24 hours (chapter 7)
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9.1 Introductie
Chronisch obstructief longlijden (C O PD ), omvat de aandoeningen chronische 
bronchitis, emfyseem en perifeer gelokaliseerde luchtwegobstructie, en wordt 
gekenmerkt door een expiratoire luchtstroom beperking. H et is 1 van de 5 meest 
voorkom ende doodsoorzaken in geïndustrialiseerde landen. C O PD  is in  het 
algemeen een progressieve aandoening. M et het voortschrijden van de ziekte kunnen 
patiënten hypoxemie en hypercapnie ontwikkelen. H et laatste is geassocieerd m et 
perioden van perifeer oedeem. Er is een noodzaak to t het nauwkeurig vervolgen en 
behandelen van hypercapnische C O PD  patiënten met tekenen van oedeem, om dat 
de prognose in het algemeen slecht is; zonder behandeling overlijdt 2 van de 3 
patienten binnen 5 jaar.
Lisdiuretica w orden frequent voorgeschreven, vanwege hun  krachtige water 
uitscheidende capaciteit. H et gebruik van lisdiuretica wordt dikwijls gecompliceerd 
door een metabole alkalose, wat ernstige consequenties kan hebben bij C O PD  
patiënten met hypoxemie en hypercapnie.
A. Een metabole alkalose geeft een verminderde chemoreceptor prikkeling. D it 
resulteert in een afgenomen alveolaire ventilatie en een stijging van de arteriële 
koolzuur spanning m et als doel het zuur/base evenwicht te stabiliseren. D it kan 
een verslechtering geven van de preëxistente hypoxemie en hypercapnie.
B. Alkalose kan mogelijk de contractiliteit van het gladde bronchusspierweefsel 
stim uleren, w aardoor een verdere bronchusconstrictie kan ontstaan. De 
preëxistente ventilatie-perfusie w anverhouding kan toenem en en de 
gasuitwisseling kan verder in gevaar komen.
O m dat hypoxemie en hyprcapnie bijdragen in de ontwikkeling van oedeem, is het 
waarschijnlijk dat een verslechtering van de zuurstof en koolzuurspanning leiden to t 
toegenomen diuretica afhankelijkheid. De veronderstelde mechanismen kunnen 
blijven bestaan of toenemen. Uiteindelijk kan er een verslechtering optreden van een 
reeds matige klinische conditie.
9.2 Hoofdstuk 2
W anneer de nachtelijke hypoxemie wordt geëvalueerd bij C O P D  patiënten, moet 
rekening worden gehouden m et het feit dat slaapapparatuur en of een onbekende 
omgeving de slaap kunnen verstoren. O m dat dit mogelijk consequenties kan hebben 
voor de waargenomen ernst van de nachtelijke hypoxemie, werd nagegaan of m inder 
desaturaties worden waargenomen tijdens een registratienacht thuis of in het
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ziekenhuis. Veertien stabiele C O P D  patiënten  ondergingen 3 verschillende 
registratienachten oximetrie in de thuissituatie, polysomnografie in de thuissituatie 
en polysomnografie in het ziekenhuis.
De mediane nachtelijke SaO 2 was lager tijdens oxmetrie dan tijdens polysomnografie 
thuis: 88,5%  (spreiding 80-92) versus 89,7%  (77-93) (p<0,05). De fractie van de tijd 
in  hypoxie (SaO2<90%) was eveneens hoger tijdens oxim etrie dan tijdens 
polysomnografie thuis. De tijd in desaturatie werd gereduceerd m et meer dan de helft 
wanneer polysomnografische apparatuur werd toegevoegd in de thuissituatie: 50,4% 
(4-91) tijdens oximetrie versus 22,1%  (3-63) tijdens polysomnografie (p<0,01). De 
vergelijking van slaaparchitectuur tijdens de PSG nachten liet een hogere arousal 
index zien in  het ziekenhuis dan thuis: 5,6 /  uur (2-16) versus 2,5 /  uur (1-6) 
(p<0,05), en m inder REM slaap als percentage van de totale slaap: 11,5% (7-27) in 
het ziekenhuis versus 17,6% (5-24) thuis (p<0,05). Er werd geen verschil gevonden 
in de nachtelijke zuurstofsaturatie tussen de beide nachten van polysomnografie.
Er werd geconcludeerd dat de verstoring ten gevolge van de slaapapparatuur kan 
bijdragen in een onderschatting van de ernst van de nachtelijke hypoxemie bij 
C O P D  patiënten. De toevoeging van een onbekende omgeving geeft extra 
slaapverstoring, maar dit leidt niet to t een verdere afwijking in de schatting van de 
nachtelijke SaO 2 .
9.3 Hoofdstuk 3
Water-verplaatsingsvolumetrie kan worden gebruikt voor het kwantificeren van 
perifeer oedeem aan de hand van het volume van het onderbeen. De toepassing bij 
patiënten m et perifeer oedeem van cardiale of pulmonale origine is nooit beschreven. 
De geschiktheid voor dit doel werd geëvalueerd, gebruik makend van water- 
verplaatsingsvolumetrie apparaat, ontw orpen in ons eigen laboratorium . De 
volum etrische resultaten w erden vergeleken m et de enkelom trek en het 
lichaamsgewicht.
De reproduceerbaarheid, vastgesteld m et een vast object en bij 10 niet-oedemateuze 
patiënten, lieten een variantie coëfficiënt zien van respectievelijk 0,16%  en 0,47% 
respectievelijk. De dagelijkse variatie, gemeten bij 10 andere patiënten met 
persisterend perifeer oedeem was 5,9% (p<0.001), vergeleken m et 2,4%  (p<0.01) 
voor de enkelomtrek, en geen significant verschil in lichaamsgewicht. H et effect van 
behandeling op de ernst van perifeer oedeem werd geëvalueerd bij 9 volgende 
patiënten m et perifeer oedeem, bij wie een indicatie bestond to t diuretische 
behandeling. H et volume, als de enkelomtrek en lichaamsgewicht daalden significant
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na behandeling: 13,1% (p<0.001), 7,1%  (p<0.05) en 5,9% (P<.0.5) respectievelijk. 
Er werd geconcludeerd dat 1) water-verplaatsingsvolumetrie zeer reproduceerbaar is, 
2) een dagelijkse variatie in perifeer oedeem kan worden waargenomen en, meest 
belangrijk, 3) volumetrie een bruikbaar en gevoelig instrum ent is om perifeer oedeem 
mee te vervolgen.
9.4 Hoofdstuk 4
Een furosemide geïnduceerde alkalose kan leiden to t een verminderde alveolaire 
ventilatie. Er werd nagegaan of het staken van furosemide zou leiden to t een daling 
van de arteriële koolzuurspanning en een stijging van de dagelijkse en nachtelijke 
oxygenatie. Furosemide, voorheen voorgeschreven voor perifeer oedeem, werd 
gestaakt gedurende 1 week bij 20 patiën ten  m et stabiel C O P D , in  een 
gerandomiseerd, dubbel blind, placebo gecontroleerd, cross-over model. Correctie 
van de alkalose resulteerde in een significante toename in ventilatie: 10,4 (6,7-15,4) 
l/m in bij aanvang versus 11,6 (8,7-14,0) l/m in na staken van furosemide (p<0,05). 
De mediane arteriële koolzuurspanning daalde m et 0,5 kPa van 6,0 (4,6-8,5) kPa bij 
aanvang to t 5,5 (4,3-8,1) kPa na staken van furosemide (p<0,01). De dagelijkse en 
nachtelijk oxygenatie verbeterden niet. Er werd geconcludeerd dat het staken van 
furosemide, voorgeschreven voor de behandeling van perifeer oedeem, een daling 
geeft van de arteriële koolzuurspanning bij patiënten m et ernstig C O PD .
9.5 Hoofdstuk 5
Metabole zuur-base veranderingen beïnvloeden mogelijk de contractiliteit van het 
gladde bronchusspierweefsel en kunnen daardoor de doorgankelijkheid van de 
luchtwegen veranderen. D it hoofdstuk beschrijft de effecten van acute metabole 
zuur-base veranderingen op de luchtweg weerstand en de luchtweg conductantie bij 
15 gezonde proefpersonen in een in een dubbel blind, placebo gecontroleerde studie. 
De bronchiale respons op histamine, de functie van de ademhalingsspieren en de 
knijpkracht werden gemeten als secundaire eindpunten. Een acute metabole alkalose 
werd uitgelokt door innam e van een berekende hoeveelheid bicarbonaat, een acidose 
door am m onium  chloride. Er werd gestreefd naar een verschil in  base overschot van 
2 mm ol/l in  beide richtingen. De innam e van fysiologisch zout werd gebruikt als 
placebo. H et base overschot nam  toe van -0 ,3  (-3,0-1,9) to t 3,0 (1,0-4,8) tijdens 
alkalose en nam  af van -0 ,2  (-2,0-2,2) to t -3 ,5  (-6,3-1,1) tijdens acidose. De 
luchtwegweerstand nam licht toe tijdens alkalose: 0,156 (0,134-0,263) kPa.s/l bij
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aanvang to t 0,169 (0,132-0,271). De conductantie nam af, echter niet statistisch 
significant. De verschillen tijdens acidose waren in tegengestelde richting vergeleken 
m et de alkalose, echter deze bereikten geen statistische significantie. De kleine 
verschillen suggereren dat een fysiologisch effect van zuur/base veranderingen 
bestaat. Er werden geen effecten gevonden van de interventies op de bronchiale 
respons op histamine, de functie van de ademhalingsspieren en de knijpkracht. Er 
werd geconcludeerd dat geringe effecten van acute metabole zuur-base veranderingen 
op de doorgankelijkheid van de luchtwegen aanwezig zijn bij gezonde proefpersonen.
9.6 Hoofdstuk 6
De effecten van metabole zuur-base veranderingen op de doorgankelijkheid van de 
luchtwegen werd vervolgens geëvalueerd bij patiënten m et astma of C O PD . Dezelfde 
interventies werden gebruikt, zoals beschreven in hoofdstuk 5. Bovendien werd een 
acute metabole alkalose uitgelokt m et furosemide. D it laatste werd toegevoegd om  de 
klinische relevantie van d it type alkalose in te schatten op de doorgankelijkheid van 
de luchtwegen.
Negentien deelnemers participeerden in een dubbel blind, placebo gecontroleerde 
studie. De groep bestond uit 12 astma patiënten (8 V, gemiddelde leeftijd 39 (±SD 
12) jaar, FEV 1 93 (±9) % voorspeld, PC 20 histamine 1.9 (±1.0) mg/ml) en 7 C O PD  
patiënten (3 V, leeftijd 60 (±8) jaar, FEV 1 54 (±15) % voorspeld). Veranderingen in 
de luchtwegweerstand (R.w), specifieke luchtweg conductantie (sGaw), FEV 1 and 
PEF werden gemeten als primaire variabelen. PC 20 histamine werd gemeten als 
secundaire variabele bij astma.
Tijdens acidose nam BE af van -0.4 (±1.3) to t -4.2 (±1.4) mm ol/l (p<0.01). sG.w en 
PEF nam en toe (alle deelnemers): 0.90 (±0.4) vs. 1.00 (±0.4) 1/kPa.s en 6.90 (±2.2) 
vs. 7.15 (±2.1) l/sec respectievelijk (beide p<0.05). Tijdens alkalose (bicarbonaat) 
nam  BE toe van +0.5 (±1.3) to t +3.8 (±1.5) m m ol/l (p<0.01), echter statistisch 
significante veranderingen in de primaire variabelen werden niet waargenomen. 
W anneer de gehele reeks zuur-base veranderingen werd geëvalueerd, werden 
statistisch significante correlaties gevonden tussen de delta BE en respectievelijk de
delta FEV 1 (r=-0.37, p<0.05), delta Raw (r= +0.39, p<0.05) en delta PEF (r=-0.45, 
p<0.01). PC 20 histamine veranderde niet.
Er werd geconcludeerd dat acute metabole zuur-base veranderingen een gering effect 
hebben op de doorgankelijkheid van de luchtwegen bij patiënten m et astma of
C O PD .
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9.7 Hoofdstuk 7
Hypercapnie speelt een belangrijke rol in het ontstaan van oedemen bij C O PD . H et 
effect van daling in de arteriële koolzuurspanning, door niet-invasieve beademing, op 
de eliminatie van vocht werd geëvalueerd in dit hoofdstuk. Vijftien stabiele chronisch 
hypercapnische C O PD  patiënten kregen 'bilevel positive airway pressure’ (BiPAP), 
via een neusmasker zo veel als werd getolereerd door de individuele patiënten, 
gedurende 24 uur. Alle patiënten verdroegen de behandeling goed. De PaCO 2 daalde 
van 6.77 (0.4) kPa bij aanvang to t 6.13 (0.4) kPa om 17.00 (p<0.01) en 6.39 (0.4) 
kPa aan het eind van de behandeling (beide p<0.01, vergeleken m et aanvang). 
Patiënten m et de ernstigste graad hypercapnie hadden de beste respons (r=0.66, 
p<0.05). De aldosteron waarden daalden, echter niet statistisch significant (0.64 
versus 0.49 nmol/l, p=0 .14). Er werden geen significante verschillen gevonden in de 
andere variabelen.
De conclusie was dat niet-invasive ventilatie kan gebruikt worden als instrum ent voor 
de behandeling van chronische hypercapnie bij C O PD , maar een interventie van 24 
uur lijkt niet voldoende om oedemen te verminderen.
9.8 Klinische relevantie en aanbevelingen
H et gebruik van furosemide is geassocieerd m et een verminderde alveolaire ventilatie 
en hiermee een stijging in de arteriële koolzuurspanning bij patiënten m et C O PD . 
D it is in overeenkomst m et de hypothese (figuur 1, fenomeen A). Een toename in de 
koolzuurspanning kan consequenties hebben voor de lange term ijn m orbiditeit en 
mortaliteit. De resultaten zijn daarom van klinisch belang, m et name bij C O PD  
patiënten met een neiging to t koolzuur stapeling. De behandelaar dient zich bewust 
te zijn van het onderdrukkend effect op de ademhaling, voordat overgegaan wordt 
to t het voorschrijven van lisdiuretica aan een patiënt m et C O PD . H et staken van 
furosemide ging niet gepaard m et een verbetering in de oxygenatie, hetgeen in 
discrepantie was m et het positieve effect van de toename in alveolaire ventilatie. H et 
is waarschijnlijk dat tegengestelde mechanismen een rol hebben gespeeld, zoals 1) een 
verslechterde diffusie capaciteit voor zuurstof, door toename van interstitiëel vocht in 
de long, of 2) een toegenomen ventilatie /  perfusie wanverhouding, door verdikking 
van de bronchuswand, verminderde sputum  klaring of afgenomen functionele 
residuale capaciteit (figuur 1, fenomeen C en D respectievelijk). Furosemide heeft 
een negatief effect op de alveolaire ventilatie, maar heeft klaarblijkelijk positieve 
aanvullende effecten op de gasuitwisseling. D it suggereert dat C O PD  patiënten
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mogelijk baat hebben bij andere typen diuretica, zonder complicerende alkalose.
Een effect van metabole zuur/base veranderingen op de hum ane luchtweg- 
doorgankelijkheid werd eveneens aangetoond. D e veranderingen waren statistisch 
significant maar vrij klein, hetgeen suggereert dat het effect (figuur 1, fenomeen B) 
slechts van geringe klinische betekenis is bij gezonde personen. Bij patiënten met 
astma of C O P D  lijken acute metabole zuur-base veranderingen slechts een gering 
effect te hebben op de doorgankelijkheid van de luchtwegen.
Figuur 1. Herzien model over vocht homeostase, zuur/base regulatie en ademhalingsregulatie bijCOPD  
A: Aanwezig bij patiënten met CO PD  (hoofdstuk 4)
B: Fysiologisch fenomeen (hoofdstuk 5), van geringe klinische relevantie bij CO PD  (hoofdstuk 6) 
C: Gesuggereerd effect (hoofdstuk 4)
D: Gesuggeerd effect (hoofdstuk 5)
E: Niet aanwezig, wanneer geobserveerd gedurende 24 uur (hoofdstuk 7)
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Mechanische ventilatie kan noodzakelijk zijn wanneer de standaard behaneling niet 
in  staat is de gasuitwisseling binnen acceptabele grenzen te houden. Alhoewel 
onvoldoende om  oedemen te verbeteren (figuur 1, fenomeen E), bleek 24 uurs niet­
invasive ventilatie goed te worden verdragen en effectief voor de behandeling van 
hypercapnie. Gezien de gegevens uit de literatuur over de levensverwachting van 
hypercapnische C O P D  patiënten, en gezien de eenvoudige procedure van 
ademhalingsondersteuning, kan de behandeling worden overwogen bij chronisch 
hypercapnische C O P D  patiënten.
9.9 Algemene conclusie
Er blijken klinische relevante interacties te bestaan tussen vocht homeostase, 
zuur/base regulatie en ademhalingsregulatie bij C O P D  patiënten. Inzicht in  deze 
interacties kan aanknopingspunten verschaffen om de klinische verslechtering bij 
patienten te helpen voorkomen. H et gebruik van furosemide bij ernstig C O P D  dient 
te worden herbeschouwd, vanwege het ventilatoir onderdrukkend effect. Bovendien 
kan de alkalose ten gevolg van lisdiuretica de gasuitwisseling verder in  gevaar brengen 
door het beïnvloeden van de bronchusconstrictie. Echter het laatste bleek slechts van 
geringe betekenis. Andere diuretica lijken van waarde, m aar aanvullend onderzoek is 
noodzakelijk om de optimale diuretische strategie bij patiënten m et ernstig C O P D  
en oedeem vast te stellen.
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Folkert Brijker werd geboren op 11 november 1969 te Ferwerd. Hij voltooide zijn 
V W O  examen in 1989 aan de Rijksscholengemeenschap Simon Vestdijk te 
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hij door in het St. Elisabeth Hospitaal te Curaçao. Na afronding van het keuze 
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H et wetenschappelijk onderzoek waarop d it proefschrift werd gebaseerd werd 
uitgevoerd op diverse afdelingen van diverse ziekenhuizen; Arnhem, Groesbeek, Velp 
en Zevenaar. Ik ben in  de gelegenheid gesteld om de verschillende kwaliteiten en 
capaciteiten te benutten. Ik heb van vele vrijwillige medewerkers een grote inzet naast 
de reguliere patientenzorg gevraagd. Overal en altijd heb ik kunnen rekenen op 
ontzettend veel steun en vooral op een zeer prettige samenwerking. Een uitm untende 
samenwerking in de regio.
Allereerst gaat mijn dank u it naar de patiënten en gezonde proefpersonen die hebben 
meegewerkt aan de verschillende onderzoeken. Altijd kon ik rekenen op inzet, zonder 
jullie was d it proefschrift niet to t stand gekomen.
Dr. F.J.J. van den Elshout. Beste Frank, vanaf het begin heb je  me gesteund en 
vertrouwen gegeven. Je hebt steeds creatief gezocht naar ruim te en mogelijkheden om 
de voortgang van het promotieonderzoek te kunnen waarborgen. Je hebt niet alleen 
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Anne-May voor al die gezellige m om enten aan de etenstafel. Frank, je  bent een 
geweldige opleider.
Prof. Dr. H .Th.M . Folgering. Beste Hans, je  enthousiasme heeft me geweldig veel 
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toegankelijkheid, je  probleemoplossend vermogen en als mens.
Dr. Y. F. Heijdra. Beste Yvonne, je  stond aan de inhoudelijke basis van het project. 
Ik  heb m oeten wennen aan je  soms erg kritische noot, maar m oet tegelijk toegeven 
dat het altijd opbouwend was. Zelfs vanuit Boston heb je  bijgedragen aan de kwaliteit 
van de stukken. Ik kreeg van jou  altijd een snel en doeltreffend antwoord op m ijn 
vragen. D ank voor alles wat ik van je  heb geleerd.
Maatschap longartsen Rijnstate. Beste Eric, Frits, Hans, M aarten en Peter, jullie 
hebben me de ruim te gegeven om m ijn werk te doen, ook al kon ik jullie lang niet 
altijd op de hoogte stellen van de voortgang. Bedankt voor de inbreuk die ik heb 
mogen doen in al die poli’s. Bedankt ook voor de gelegenheid waarin ik ben gesteld 
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Marielle en Jouke, m ijn paranimfen. Een m arkant duo, elkaar perfect aanvullend. 
D ank voor jullie steun. Ik hoop nog veel m et jullie te kunnen meemaken.
De leden van de manuscriptcommissie Prof. Dr. P. Smits, Prof. Dr. C.L.A. van 
Herwaarden en Prof. Dr. W. DeBacker, dank ik voor de tijd en aandacht die zij 
hebben besteed aan de beoordeling van het proefschrift.
Mirjam, m ijn lieve echtgenote. Geduldig heb je  de vorderingen afgewacht, ook al 
duldde je  geen thuiswerk. Dankzij jo u  was de prom otietijd een periode m et veel 
afwisseling, zonder zwoegen. We hebben het goed, zullen we zo m aar doorgaan? 
M ijn ouders, lieve pappe en mem, ik heb van jullie altijd de ruim te en steun 
gekregen. Van jullie heb ik zoveel meegekregen. Zo ook de drijfveer om iets af te 
maken. H et is gelukt.
Maaike, mijn allerliefste kleine meid. Al heb je  nog geen flauw benul, je  geeft me 
oneindig veel vreugde.
